R406	PKAC-beta	510.0	1.4	1e-06
Canertinib	EPHB4	1800.0	100.0	1e-06
Crizotinib	CSF1R	210.0	0.2	9.999999999999999e-06
NVP-TAE684	ULK1	0.8	0.1	1e-06
Canertinib	PGFRA	5200.0	100.0	1e-06
R406	TRKC	570.0	7.0	1e-06
Neratinib	EGFR	1.1	0.1	9.999999999999999e-06
Neratinib	MAP4K4	330.0	6.2	9.999999999999999e-06
NVP-TAE684	DAPK3	2200.0	4.5	1e-06
MLN8054	DRAK1	190.0	1.9	9.999999999999999e-06
Neratinib	IRAK1	2300.0	65.0	9.999999999999999e-06
R406	PRKR	180.0	4.2	1e-06
PLX-4720	ABL1(Y253F)-phosphorylated	1900.0	27.0	9.999999999999999e-06
Canertinib	SLK	1800.0	100.0	1e-06
Crizotinib	ROS1	4.1	1.1	9.999999999999999e-06
R406	KIT(V559D,T670I)	11.0	0.1	1e-06
Pictilisib	HIPK3	600.0	79.0	1.0000000000000002e-06
Barasertib	EGFR(S752-I759del)	5200.0	30.0	9.999999999999999e-06
Lapatinib	EGFR(L858R)	2.8	0.0	9.999999999999999e-06
Crizotinib	TBK1	690.0	8.7	9.999999999999999e-06
R406	EPHA7	39.0	0.1	1e-06
Neratinib	TXK	4800.0	86.0	9.999999999999999e-06
Sorafenib	CDK14	2900.0	8.6	9.999999999999999e-06
Canertinib	FLT3	2700.0	100.0	1e-06
Pictilisib	GAK	2700.0	100.0	1.0000000000000002e-06
R406	MAP3K4	840.0	13.0	1e-06
Neratinib	FGR	1900.0	40.0	9.999999999999999e-06
NVP-TAE684	TRKB	130.0	8.4	1e-06
Barasertib	CDK16	6300.0	79.0	9.999999999999999e-06
R406	TYRO3	1900.0	30.0	1e-06
Barasertib	ABL1-phosphorylated	5500.0	30.0	9.999999999999999e-06
Crizotinib	FGFR3	2700.0	22.0	9.999999999999999e-06
R406	NUAK1	75.0	0.9	1e-06
NVP-TAE684	ERK5	48.0	0.0	1e-06
NVP-TAE684	MP2K6	2000.0	100.0	1e-06
Barasertib	PGFRB	41.0	0.0	9.999999999999999e-06
NVP-TAE684	DDR2	4100.0	14.0	1e-06
NVP-TAE684	TEC	180.0	0.7	1e-06
Lapatinib	ERBB2	7.0	0.0	9.999999999999999e-06
PLX-4720	FLT3(ITD)	6100.0	68.0	9.999999999999999e-06
NVP-TAE684	LCK	49.0	0.1	1e-06
R406	AURKA	160.0	3.6	1e-06
NVP-TAE684	TTK	50.0	0.0	1e-06
R406	NEK9	16.0	0.7	1e-06
R406	ABL2	720.0	4.4	1e-06
BI-2536	RIOK1	2200.0	100.0	9.999999999999999e-06
Canertinib	VGFR1	7500.0	100.0	1e-06
Crizotinib	FLT3(D835Y)	210.0	11.0	9.999999999999999e-06
Pictilisib	IRAK3	1700.0	97.0	1.0000000000000002e-06
R406	KIT	6.8	0.0	1e-06
Sorafenib	EPHA1	3100.0	20.0	9.999999999999999e-06
PLX-4720	FLT3(K663Q)	2300.0	17.0	9.999999999999999e-06
NVP-TAE684	ERBB2	540.0	8.0	1e-06
NVP-TAE684	ACVR1	29.0	0.0	1e-06
NVP-TAE684	AXL	12.0	0.1	1e-06
NVP-TAE684	CAMK2B	1900.0	5.8	1e-06
PLX-4720	BRAF(V600E)	100.0	0.0	9.999999999999999e-06
Barasertib	CIT	5700.0	27.0	9.999999999999999e-06
BI-2536	EGFR(L747-E749del,A750P)	1100.0	20.0	9.999999999999999e-06
BI-2536	EGFR(L858R)	1300.0	24.0	9.999999999999999e-06
Neratinib	TIE2	3000.0	56.0	9.999999999999999e-06
Sorafenib	ERK8	46.0	0.9	9.999999999999999e-06
NVP-TAE684	ACVR2B	4300.0	22.0	1e-06
R406	LYN	26.0	1.5	1e-06
BMS345541	KIT(V559D)	5700.0	23.0	9.999999999999999e-06
Neratinib	NEK3	2400.0	41.0	9.999999999999999e-06
Barasertib	AURKA	400.0	6.5	9.999999999999999e-06
NVP-TAE684	MYLK	220.0	0.5	1e-06
Neratinib	MERTK	400.0	8.4	9.999999999999999e-06
Canertinib	EGFR(S752-I759del)	0.19	0.0	1e-06
NVP-TAE684	AMPK-alpha1	27.0	0.1	1e-06
Crizotinib	SIK2	200.0	12.0	9.999999999999999e-06
R406	HIPK1	820.0	9.2	1e-06
Crizotinib	TNK2	760.0	2.8	9.999999999999999e-06
NVP-TAE684	DRAK1	2900.0	5.9	1e-06
R406	PHKG2	940.0	14.0	1e-06
GSK461364	SNARK	23.0	1.2	9.999999999999999e-06
BI-2536	STK16	1100.0	14.0	9.999999999999999e-06
NVP-TAE684	DCLK1	4.9	0.0	1e-06
Sorafenib	SRMS	9800.0	72.0	9.999999999999999e-06
NVP-TAE684	KKCC1	50.0	0.2	1e-06
Sorafenib	ABL1(F317L)-phosphorylated	7100.0	36.0	9.999999999999999e-06
Sorafenib	YSK4	99.0	0.4	9.999999999999999e-06
NVP-TAE684	MARK2	44.0	4.6	1e-06
R406	MAP3K3	150.0	2.4	1e-06
MLN8054	HCK	1500.0	3.2	9.999999999999999e-06
Canertinib	EGFR	0.19	0.0	1e-06
NVP-TAE684	DYRK1B	4500.0	100.0	1e-06
MLN8054	TYRO3	3100.0	46.0	9.999999999999999e-06
PLX-4720	PAK1	1400.0	11.0	9.999999999999999e-06
R406	STK36	230.0	1.4	1e-06
NVP-TAE684	BIKE	1900.0	2.8	1e-06
Canertinib	RET	4200.0	100.0	1e-06
Sorafenib	HIPK1	3300.0	13.0	9.999999999999999e-06
R406	PGFRA	60.0	0.2	1e-06
R406	SLK	33.0	0.1	1e-06
R406	FLT3(D835H)	0.7	0.1	1e-06
Neratinib	EGFR(E746-A750del)	2.3	2.8	9.999999999999999e-06
Sorafenib	TRKB	2100.0	13.0	9.999999999999999e-06
R406	FRK	68.0	1.6	1e-06
BI-2536	DAPK2	930.0	16.0	9.999999999999999e-06
BI-2536	NEK2	2000.0	17.0	9.999999999999999e-06
Crizotinib	LOK	44.0	0.0	9.999999999999999e-06
Crizotinib	ABL1(T315I)-nonphosphorylated	12.0	0.0	9.999999999999999e-06
NVP-TAE684	HCK	410.0	0.4	1e-06
R406	TGFBR1	2600.0	33.0	1e-06
Barasertib	HIPK2	3700.0	31.0	9.999999999999999e-06
Canertinib	IRAK3	3000.0	100.0	1e-06
Canertinib	ERK4	5400.0	100.0	1e-06
R406	KPCD3	3900.0	23.0	1e-06
NVP-TAE684	CAMKK2	11.0	0.1	1e-06
Canertinib	EGFR(L747-S752del,P753S)	0.26	0.1	1e-06
MLN8054	ABL1(T315I)-nonphosphorylated	1600.0	0.8	9.999999999999999e-06
NVP-TAE684	DAPK2	870.0	12.0	1e-06
Canertinib	EPHA8	2000.0	100.0	1e-06
NVP-TAE684	DCAMKL3	14.0	0.0	1e-06
NVP-TAE684	PAK2	5800.0	30.0	1e-06
Sorafenib	TIE1	68.0	4.0	9.999999999999999e-06
NVP-TAE684	TRKA	460.0	12.0	1e-06
Crizotinib	M3K13	230.0	10.0	9.999999999999999e-06
Pictilisib	DAPK3	1800.0	82.0	1.0000000000000002e-06
PLX-4720	SIK2	1900.0	84.0	9.999999999999999e-06
R406	EPHA3	360.0	12.0	1e-06
R406	TNIK	1300.0	26.0	1e-06
Barasertib	RET	80.0	0.3	9.999999999999999e-06
R406	KIT(V559D,V654A)	410.0	3.0	1e-06
NVP-TAE684	BMPR1A	170.0	0.0	1e-06
Barasertib	AURKC	4.4	19.0	9.999999999999999e-06
Sorafenib	JAK3(JH1domain-catalytic)	7300.0	58.0	9.999999999999999e-06
NVP-TAE684	YES	23.0	0.1	1e-06
Canertinib	LCK	320.0	25.0	1e-06
GSK461364	NEK2	260.0	2.4	9.999999999999999e-06
Crizotinib	ACVR1B	860.0	9.0	9.999999999999999e-06
Neratinib	CDK16	2300.0	100.0	9.999999999999999e-06
Canertinib	EPHA5	1200.0	100.0	1e-06
Sorafenib	KIT(D816H)	430.0	36.0	9.999999999999999e-06
Crizotinib	M4K3	75.0	1.3	9.999999999999999e-06
GSK461364	FLT3(D835Y)	430.0	21.0	9.999999999999999e-06
BI-2536	FAK1	150.0	2.4	9.999999999999999e-06
Neratinib	BTK	160.0	4.4	9.999999999999999e-06
Lapatinib	LOK	4400.0	1.4	9.999999999999999e-06
Canertinib	ABL2	870.0	100.0	1e-06
Canertinib	MP2K2	1600.0	100.0	1e-06
Neratinib	MST1	270.0	17.0	9.999999999999999e-06
NVP-TAE684	PAK7	390.0	2.7	1e-06
PLX-4720	VGFR1	1900.0	28.0	9.999999999999999e-06
PLX-4720	CLK1	6600.0	37.0	9.999999999999999e-06
Canertinib	SRMS	6700.0	100.0	1e-06
Crizotinib	MERTK	3.6	2.1	9.999999999999999e-06
Neratinib	CSNK1G3	7800.0	81.0	9.999999999999999e-06
BI-2536	CLK2	460.0	5.4	9.999999999999999e-06
Sorafenib	PGFRA	62.0	0.0	9.999999999999999e-06
R406	MLK3	11.0	0.2	1e-06
NVP-TAE684	CDK16	560.0	2.2	1e-06
Canertinib	KIT(V559D)	7900.0	100.0	1e-06
MLN8054	ABL1-phosphorylated	890.0	8.6	9.999999999999999e-06
PLX-4720	MP2K2	1100.0	1.0	9.999999999999999e-06
Crizotinib	ADCK4	1100.0	3.4	9.999999999999999e-06
R406	CAMK1	230.0	2.8	1e-06
NVP-TAE684	SLK	21.0	0.1	1e-06
R406	AAK1	410.0	12.0	1e-06
Sorafenib	CDK7	140.0	4.2	9.999999999999999e-06
NVP-TAE684	EPHA2	890.0	27.0	1e-06
Crizotinib	SLK	18.0	0.1	9.999999999999999e-06
R406	MET	280.0	1.0	1e-06
Barasertib	EPHB6	50.0	0.8	9.999999999999999e-06
MLN8054	BMX	3100.0	26.0	9.999999999999999e-06
BMS345541	RPS6KA4(Kin.Dom.2-C-terminal)	2300.0	15.0	9.999999999999999e-06
Neratinib	MAP3K3	130.0	3.8	9.999999999999999e-06
NVP-TAE684	INSRR	6.2	0.4	1e-06
R406	MK13	690.0	0.0	1e-06
PLX-4720	KIT(D816V)	3100.0	49.0	9.999999999999999e-06
R406	LATS2	4000.0	33.0	1e-06
Pictilisib	HIPK4	5000.0	87.0	1.0000000000000002e-06
Barasertib	CDC2L5	1100.0	66.0	9.999999999999999e-06
Pictilisib	PIK3CA(H1047L)	3.7	0.8	1.0000000000000002e-06
R406	EPHA8	1300.0	6.3	1e-06
R406	EGFR(L861Q)	190.0	0.8	1e-06
Neratinib	JNK1	3300.0	16.0	9.999999999999999e-06
Sorafenib	ABL1(E255K)-phosphorylated	3400.0	47.0	9.999999999999999e-06
R406	FGR	33.0	1.6	1e-06
Barasertib	RIPK5	3000.0	14.0	9.999999999999999e-06
Barasertib	AAK1	3000.0	38.0	9.999999999999999e-06
Neratinib	EGFR(L858R,T790M)	27.0	20.0	9.999999999999999e-06
PLX-4720	ABL1(H396P)-phosphorylated	5000.0	53.0	9.999999999999999e-06
BI-2536	EGFR	2200.0	100.0	9.999999999999999e-06
BI-2536	CAMK2B	4200.0	100.0	9.999999999999999e-06
Crizotinib	TESK1	380.0	3.4	9.999999999999999e-06
Barasertib	ABL1(T315I)-nonphosphorylated	1100.0	0.6	9.999999999999999e-06
Neratinib	STK35	4500.0	81.0	9.999999999999999e-06
GSK461364	PIK3CB	2000.0	0.8	9.999999999999999e-06
R406	FLT3	0.7	0.0	1e-06
PLX-4720	TNK2	1100.0	8.2	9.999999999999999e-06
Barasertib	KIT(D816V)	4600.0	23.0	9.999999999999999e-06
Neratinib	LOK	13.0	0.0	9.999999999999999e-06
NVP-TAE684	KPCD	3500.0	28.0	1e-06
Barasertib	CDKL2	1200.0	18.0	9.999999999999999e-06
PLX-4720	DDR2	4100.0	15.0	9.999999999999999e-06
Neratinib	LYN	820.0	34.0	9.999999999999999e-06
NVP-TAE684	AURKC	33.0	0.1	1e-06
NVP-TAE684	WEE1	3000.0	17.0	1e-06
Crizotinib	IKKE	710.0	60.0	9.999999999999999e-06
R406	EGFR(L747-T751del,Sins)	340.0	2.7	1e-06
NVP-TAE684	FGFR1	47.0	0.0	1e-06
Barasertib	EGFR	450.0	3.8	9.999999999999999e-06
Neratinib	MET(Y1235D)	4200.0	86.0	9.999999999999999e-06
MLN8054	ABL1(M351T)-phosphorylated	750.0	8.6	9.999999999999999e-06
Sorafenib	HCK	8500.0	27.0	9.999999999999999e-06
R406	EGFR(E746-A750del)	1100.0	8.2	1e-06
BI-2536	KC1G1	4500.0	100.0	9.999999999999999e-06
MLN8054	FGFR3	1200.0	9.0	9.999999999999999e-06
BI-2536	SYK	4700.0	100.0	9.999999999999999e-06
NVP-TAE684	EPHA1	39.0	0.2	1e-06
BMS345541	ERK3	4300.0	27.0	9.999999999999999e-06
Pictilisib	PIK3CA(C420R)	1.5	0.0	1.0000000000000002e-06
Neratinib	TNK2	680.0	40.0	9.999999999999999e-06
Sorafenib	M4K1	4800.0	41.0	9.999999999999999e-06
Barasertib	VGFR1	110.0	1.0	9.999999999999999e-06
Neratinib	ABL1(Q252H)-nonphosphorylated	7100.0	71.0	9.999999999999999e-06
NVP-TAE684	MKNK2	44.0	1.4	1e-06
Neratinib	EGFR(G719C)	0.4	0.0	9.999999999999999e-06
Neratinib	TAOK3	4200.0	75.0	9.999999999999999e-06
GSK461364	IRAK3	3500.0	38.0	9.999999999999999e-06
Sorafenib	NLK	640.0	32.0	9.999999999999999e-06
BI-2536	CDK7	3500.0	100.0	9.999999999999999e-06
Barasertib	KIT(V559D)	15.0	0.0	9.999999999999999e-06
Crizotinib	MST2	990.0	0.0	9.999999999999999e-06
GSK461364	CAMK2B	2900.0	19.0	9.999999999999999e-06
Barasertib	FLT4	2900.0	38.0	9.999999999999999e-06
R406	ADCK3	1100.0	14.0	1e-06
NVP-TAE684	BMX	1100.0	12.0	1e-06
MLN8054	EPHB3	3500.0	29.0	9.999999999999999e-06
BI-2536	MYO3A	6300.0	100.0	9.999999999999999e-06
Crizotinib	FER	270.0	2.0	9.999999999999999e-06
Barasertib	FLT3	8.2	0.4	9.999999999999999e-06
NVP-TAE684	ANKK1	9400.0	100.0	1e-06
R406	RET(V804L)	2.2	0.0	1e-06
GSK461364	ULK2	1400.0	11.0	9.999999999999999e-06
MLN8054	ABL1(Q252H)-nonphosphorylated	630.0	0.9	9.999999999999999e-06
Sorafenib	CDK15	2900.0	19.0	9.999999999999999e-06
GSK461364	CSNK2A1	7300.0	13.0	9.999999999999999e-06
Neratinib	RSK3(Kin.Dom.1-N-terminal)	4100.0	88.0	9.999999999999999e-06
Sorafenib	PFCDPK1(P.falciparum)	220.0	1.0	9.999999999999999e-06
R406	ROS1	29.0	0.2	1e-06
Canertinib	EPHB1	1500.0	100.0	1e-06
NVP-TAE684	EPHB3	1900.0	18.0	1e-06
Crizotinib	FGR	670.0	6.8	9.999999999999999e-06
Sorafenib	MYO3B	7100.0	28.0	9.999999999999999e-06
NVP-TAE684	CHEK1	44.0	0.0	1e-06
Crizotinib	CDKL2	2100.0	5.4	9.999999999999999e-06
Sorafenib	EPHA6	370.0	9.2	9.999999999999999e-06
NVP-TAE684	PLK4	0.9	0.0	1e-06
NVP-TAE684	NDR2	580.0	7.3	1e-06
NVP-TAE684	DMPK2	9500.0	23.0	1e-06
Sorafenib	LYN	3000.0	16.0	9.999999999999999e-06
GSK461364	KPCD	3000.0	22.0	9.999999999999999e-06
Sorafenib	DDR1	1.5	0.0	9.999999999999999e-06
PLX-4720	RAF1	170.0	3.4	9.999999999999999e-06
Crizotinib	ABL1-nonphosphorylated	78.0	0.0	9.999999999999999e-06
NVP-TAE684	MLK2	1100.0	4.6	1e-06
NVP-TAE684	MK01	300.0	0.3	1e-06
PLX-4720	FLT3(R834Q)	3000.0	100.0	9.999999999999999e-06
NVP-TAE684	PGFRA	840.0	0.9	1e-06
GSK461364	KIT(A829P)	7200.0	29.0	9.999999999999999e-06
GSK461364	CAMK2G	1300.0	15.0	9.999999999999999e-06
R406	TIE2	310.0	0.5	1e-06
Sorafenib	ABL1(M351T)-phosphorylated	1200.0	21.0	9.999999999999999e-06
R406	INSRR	4600.0	9.2	1e-06
NVP-TAE684	MYO3B	81.0	0.6	1e-06
R406	PKN1	660.0	1.8	1e-06
Lapatinib	EGFR(G719C)	0.9	0.1	9.999999999999999e-06
R406	TNNI3K	310.0	1.9	1e-06
GSK461364	BIKE	470.0	1.0	9.999999999999999e-06
NVP-TAE684	ADCK4	92.0	0.0	1e-06
BI-2536	CAMK2G	1200.0	100.0	9.999999999999999e-06
GSK461364	NIM1	6400.0	30.0	9.999999999999999e-06
GSK461364	MLK1	3000.0	17.0	9.999999999999999e-06
NVP-TAE684	MAP4K5	190.0	0.3	1e-06
Barasertib	TIE1	350.0	6.6	9.999999999999999e-06
PLX-4720	NEK2	5000.0	49.0	9.999999999999999e-06
R406	CDKL2	5900.0	24.0	1e-06
MLN8054	CSK	9000.0	15.0	9.999999999999999e-06
Pictilisib	MK09	1800.0	98.0	1.0000000000000002e-06
NVP-TAE684	CDK5	1600.0	5.2	1e-06
GSK461364	PIK3CD	3100.0	14.0	9.999999999999999e-06
Sorafenib	TAOK3	2700.0	0.8	9.999999999999999e-06
R406	FAK2	29.0	0.3	1e-06
Crizotinib	ERK5	510.0	0.1	9.999999999999999e-06
R406	AURKC	41.0	0.3	1e-06
R406	ULK2	19.0	4.6	1e-06
PLX-4720	CDK8	1900.0	2.2	9.999999999999999e-06
R406	ZAP70	21.0	0.0	1e-06
Canertinib	TNIK	8200.0	100.0	1e-06
R406	PKAC-alpha	600.0	1.8	1e-06
R406	FLT3(ITD)	0.5	0.0	1e-06
Crizotinib	MET(M1250T)	0.6	0.1	9.999999999999999e-06
R406	MERTK	170.0	0.3	1e-06
NVP-TAE684	CSNK1A1L	5200.0	100.0	1e-06
Crizotinib	TGFBR1	1000.0	4.0	9.999999999999999e-06
Pictilisib	PIK3CA(M1043I)	4.5	0.4	1.0000000000000002e-06
NVP-TAE684	DAPK1	1800.0	6.4	1e-06
Crizotinib	HIPK4	3600.0	15.0	9.999999999999999e-06
Barasertib	SRMS	7900.0	29.0	9.999999999999999e-06
NVP-TAE684	FGFR3(G697C)	120.0	0.3	1e-06
MLN8054	FGFR2	1700.0	7.7	9.999999999999999e-06
Sorafenib	MAP4K5	1600.0	7.2	9.999999999999999e-06
Crizotinib	VGFR1	2300.0	25.0	9.999999999999999e-06
R406	TRKB	900.0	4.8	1e-06
NVP-TAE684	MP2K1	550.0	3.6	1e-06
Lapatinib	PIK3C2B	670.0	39.0	9.999999999999999e-06
GSK461364	RSK2(Kin.Dom.1-N-terminal)	190.0	0.5	9.999999999999999e-06
R406	EPHB2	880.0	100.0	1e-06
Canertinib	KIT	7800.0	100.0	1e-06
Crizotinib	TYK2(JH1domain-catalytic)	210.0	14.0	9.999999999999999e-06
Barasertib	MP2K1	1900.0	32.0	9.999999999999999e-06
R406	FES	200.0	2.6	1e-06
Canertinib	KIT(D816V)	3900.0	100.0	1e-06
R406	KIT(D816V)	2.5	0.2	1e-06
GSK461364	PKN2	620.0	6.0	9.999999999999999e-06
Crizotinib	ABL1(F317L)-nonphosphorylated	610.0	0.0	9.999999999999999e-06
Neratinib	MLTK	1500.0	70.0	9.999999999999999e-06
GSK461364	MAP4K2	3200.0	24.0	9.999999999999999e-06
Canertinib	AXL	5700.0	100.0	1e-06
Crizotinib	AMPK-alpha1	2400.0	8.0	9.999999999999999e-06
Crizotinib	CDK7	330.0	1.2	9.999999999999999e-06
Sorafenib	RET(M918T)	7.4	0.1	9.999999999999999e-06
Sorafenib	TGFBR2	6900.0	35.0	9.999999999999999e-06
NVP-TAE684	INSR	2.4	0.0	1e-06
NVP-TAE684	M3K12	42.0	0.0	1e-06
R406	WEE1	890.0	7.8	1e-06
PLX-4720	ABL1(F317I)-nonphosphorylated	1300.0	5.8	9.999999999999999e-06
Sorafenib	EPHA8	2400.0	3.9	9.999999999999999e-06
MLN8054	EPHA1	1800.0	15.0	9.999999999999999e-06
Canertinib	BTK	1600.0	100.0	1e-06
PLX-4720	LIMK2	620.0	24.0	9.999999999999999e-06
R406	LIMK1	620.0	6.2	1e-06
Neratinib	MET(M1250T)	6700.0	47.0	9.999999999999999e-06
Neratinib	GCN2(Kin.Dom.2,S808G)	96.0	1.4	9.999999999999999e-06
Crizotinib	CDC2L2	420.0	0.4	9.999999999999999e-06
Crizotinib	MST1	580.0	3.9	9.999999999999999e-06
NVP-TAE684	MARK4	12.0	0.0	1e-06
Crizotinib	ABL1(H396P)-phosphorylated	87.0	0.0	9.999999999999999e-06
NVP-TAE684	PKN1	340.0	0.5	1e-06
Neratinib	DRAK1	340.0	37.0	9.999999999999999e-06
R406	RIOK3	210.0	0.9	1e-06
Neratinib	JNK3	2500.0	27.0	9.999999999999999e-06
R406	AMPK-alpha1	300.0	2.6	1e-06
R406	EGFR(L747-S752del,P753S)	560.0	5.0	1e-06
R406	TEC	1600.0	1.4	1e-06
MLN8054	BTK	4200.0	28.0	9.999999999999999e-06
Canertinib	MLTK	1200.0	100.0	1e-06
Pictilisib	FLT3(ITD)	2200.0	79.0	1.0000000000000002e-06
Crizotinib	FLT3(K663Q)	900.0	5.6	9.999999999999999e-06
Neratinib	FLT3(D835Y)	3100.0	89.0	9.999999999999999e-06
GSK461364	SRPK3	7600.0	9.6	9.999999999999999e-06
Crizotinib	TNNI3K	110.0	2.4	9.999999999999999e-06
GSK461364	CAMK2A	1000.0	4.9	9.999999999999999e-06
NVP-TAE684	CAMK1	1100.0	1.4	1e-06
NVP-TAE684	PHKG2	13.0	0.0	1e-06
MLN8054	TNK1	2400.0	16.0	9.999999999999999e-06
R406	EPHA4	150.0	12.0	1e-06
Crizotinib	EPHB1	120.0	0.2	9.999999999999999e-06
Sorafenib	AURKB	440.0	0.7	9.999999999999999e-06
MLN8054	FLT3(K663Q)	9500.0	68.0	9.999999999999999e-06
PLX-4720	HIPK3	9700.0	46.0	9.999999999999999e-06
Pictilisib	FLT3(D835H)	1700.0	79.0	1.0000000000000002e-06
R406	RIOK1	340.0	0.9	1e-06
MLN8054	ABL1(E255K)-phosphorylated	1900.0	13.0	9.999999999999999e-06
Sorafenib	TAK1	690.0	6.2	9.999999999999999e-06
Crizotinib	CDC2L1	760.0	0.1	9.999999999999999e-06
Sorafenib	ABL1(F317L)-nonphosphorylated	770.0	5.4	9.999999999999999e-06
R406	MP2K2	730.0	20.0	1e-06
Crizotinib	EGFR(L861Q)	2700.0	82.0	9.999999999999999e-06
Crizotinib	TIE2	270.0	1.0	9.999999999999999e-06
Sorafenib	CLK1	7500.0	23.0	9.999999999999999e-06
Neratinib	EGFR(S752-I759del)	0.6	0.1	9.999999999999999e-06
NVP-TAE684	MK03	430.0	0.1	1e-06
MLN8054	LOK	3700.0	6.7	9.999999999999999e-06
Canertinib	EGFR(L747-E749del,A750P)	0.17	0.0	1e-06
PLX-4720	SGK3	7200.0	49.0	9.999999999999999e-06
GSK461364	PIM3	1100.0	11.0	9.999999999999999e-06
NVP-TAE684	KPCD3	90.0	0.0	1e-06
R406	WEE2	9400.0	1.6	1e-06
Canertinib	RIOK1	8400.0	100.0	1e-06
R406	TIE1	76.0	0.3	1e-06
NVP-TAE684	MINK	330.0	100.0	1e-06
Canertinib	STK36	4500.0	100.0	1e-06
GSK461364	RPS6KA4(Kin.Dom.2-C-terminal)	740.0	0.6	9.999999999999999e-06
Neratinib	FAK2	8000.0	90.0	9.999999999999999e-06
Barasertib	YSK4	2400.0	39.0	9.999999999999999e-06
Neratinib	GAK	250.0	10.0	9.999999999999999e-06
BMS345541	CDC2L1	420.0	1.0	9.999999999999999e-06
Barasertib	ABL1(Q252H)-nonphosphorylated	860.0	1.7	9.999999999999999e-06
NVP-TAE684	ADCK3	1700.0	9.2	1e-06
Crizotinib	SBK1	1300.0	6.0	9.999999999999999e-06
Barasertib	DDR1	1800.0	12.0	9.999999999999999e-06
R406	RIPK4	220.0	17.0	1e-06
R406	M4K3	2400.0	13.0	1e-06
Lapatinib	EGFR(L747-T751del,Sins)	3.5	0.5	9.999999999999999e-06
Pictilisib	CAMK1	4700.0	100.0	1.0000000000000002e-06
R406	NEK5	13.0	0.1	1e-06
NVP-TAE684	KIT(V559D)	81.0	0.1	1e-06
R406	TTK	1100.0	20.0	1e-06
R406	TLK2	380.0	7.4	1e-06
BI-2536	EGFR(E746-A750del)	1900.0	8.4	9.999999999999999e-06
Sorafenib	KIT(L576P)	25.0	0.0	9.999999999999999e-06
Barasertib	TAK1	650.0	16.0	9.999999999999999e-06
BI-2536	MYO3B	3500.0	100.0	9.999999999999999e-06
Sorafenib	KIT	28.0	0.0	9.999999999999999e-06
Sorafenib	PCTK2	1600.0	17.0	9.999999999999999e-06
R406	PLK1	830.0	6.4	1e-06
PLX-4720	ACVR2B	3200.0	28.0	9.999999999999999e-06
Sorafenib	MP2K5	190.0	0.3	9.999999999999999e-06
Crizotinib	NEK7	5700.0	6.7	9.999999999999999e-06
PLX-4720	CSF1R	2700.0	2.2	9.999999999999999e-06
GSK461364	FLT3(D835H)	410.0	10.0	9.999999999999999e-06
Neratinib	ERBB4	2.4	0.0	9.999999999999999e-06
R406	SRMS	610.0	16.0	1e-06
Barasertib	TNIK	8500.0	52.0	9.999999999999999e-06
PLX-4720	ABL1(F317L)-nonphosphorylated	940.0	7.0	9.999999999999999e-06
Barasertib	ABL1(Y253F)-phosphorylated	3800.0	28.0	9.999999999999999e-06
Canertinib	EGFR(L858R)	0.24	0.0	1e-06
Pictilisib	MYLK4	780.0	52.0	1.0000000000000002e-06
R406	CSK	160.0	2.2	1e-06
NVP-TAE684	RIPK4	3200.0	100.0	1e-06
PLX-4720	PIK4CB	1200.0	25.0	9.999999999999999e-06
Barasertib	MET(Y1235D)	5700.0	30.0	9.999999999999999e-06
Barasertib	STK36	4600.0	37.0	9.999999999999999e-06
R406	MKNK1	230.0	0.2	1e-06
Crizotinib	IRAK4	3600.0	24.0	9.999999999999999e-06
Crizotinib	TAOK3	490.0	1.4	9.999999999999999e-06
NVP-TAE684	PAK3	29.0	0.9	1e-06
Crizotinib	ABL1(F317I)-nonphosphorylated	2700.0	0.0	9.999999999999999e-06
BI-2536	CLK1	940.0	100.0	9.999999999999999e-06
Pictilisib	PIK3C2G	300.0	17.0	1.0000000000000002e-06
Pictilisib	RSK4(Kin.Dom.1-N-terminal)	5400.0	100.0	1.0000000000000002e-06
NVP-TAE684	KIT	110.0	0.1	1e-06
NVP-TAE684	TNK1	1.8	0.5	1e-06
PLX-4720	HIPK2	5000.0	20.0	9.999999999999999e-06
R406	DCAMKL3	600.0	1.0	1e-06
Crizotinib	MAP3K15	2800.0	73.0	9.999999999999999e-06
BI-2536	EGFR(S752-I759del)	5300.0	30.0	9.999999999999999e-06
Barasertib	FLT3(R834Q)	130.0	14.0	9.999999999999999e-06
Sorafenib	MKNK1	230.0	2.1	9.999999999999999e-06
Sorafenib	EPHB1	3000.0	30.0	9.999999999999999e-06
NVP-TAE684	ROCK2	130.0	1.0	1e-06
Pictilisib	DAPK1	4000.0	77.0	1.0000000000000002e-06
BMS345541	IKKB	130.0	0.6	9.999999999999999e-06
Crizotinib	FRK	2900.0	15.0	9.999999999999999e-06
Sorafenib	MYLK2	5400.0	43.0	9.999999999999999e-06
BI-2536	EGFR(L747-S752del,P753S)	6300.0	18.0	9.999999999999999e-06
Pictilisib	PIK3CB	16.0	0.0	1.0000000000000002e-06
Neratinib	KPCD3	2400.0	65.0	9.999999999999999e-06
NVP-TAE684	PLK3	210.0	0.0	1e-06
Barasertib	ABL1(M351T)-phosphorylated	2200.0	39.0	9.999999999999999e-06
R406	FGFR2	73.0	1.4	1e-06
Sorafenib	BRAF(V600E)	260.0	0.1	9.999999999999999e-06
Sorafenib	MK12	7600.0	51.0	9.999999999999999e-06
BI-2536	CLK3	630.0	29.0	9.999999999999999e-06
Barasertib	HCK	3900.0	31.0	9.999999999999999e-06
Neratinib	ABL1(Q252H)-phosphorylated	6000.0	72.0	9.999999999999999e-06
Neratinib	SYK	5100.0	65.0	9.999999999999999e-06
R406	MYLK	6500.0	100.0	1e-06
Canertinib	MAP4K5	2600.0	100.0	1e-06
GSK461364	NEK9	1100.0	10.0	9.999999999999999e-06
NVP-TAE684	TNIK	1200.0	12.0	1e-06
Neratinib	NEK2	250.0	12.0	9.999999999999999e-06
R406	GSK3A	2500.0	13.0	1e-06
PLX-4720	FLT3(D835Y)	6500.0	31.0	9.999999999999999e-06
Sorafenib	CDK2	8700.0	33.0	9.999999999999999e-06
Pictilisib	FLT3(D835Y)	710.0	89.0	1.0000000000000002e-06
GSK461364	TIE1	1400.0	20.0	9.999999999999999e-06
R406	TAOK3	4600.0	100.0	1e-06
R406	SgK110	190.0	1.6	1e-06
BI-2536	MINK	1600.0	100.0	9.999999999999999e-06
Canertinib	CSNK1D	4600.0	100.0	1e-06
Sorafenib	FLT3	13.0	0.5	9.999999999999999e-06
Crizotinib	KIT(D816V)	3700.0	32.0	9.999999999999999e-06
NVP-TAE684	BRSK2	190.0	0.5	1e-06
PLX-4720	GCN2(Kin.Dom.2,S808G)	1300.0	1.0	9.999999999999999e-06
Crizotinib	EPHA1	140.0	0.9	9.999999999999999e-06
MLN8054	ABL2	3300.0	30.0	9.999999999999999e-06
MLN8054	AXL	440.0	4.4	9.999999999999999e-06
Neratinib	FLT3	5400.0	100.0	9.999999999999999e-06
R406	TNK2	70.0	0.3	1e-06
NVP-TAE684	MARK1	31.0	0.0	1e-06
Lapatinib	EGFR(L747-S752del,P753S)	3.9	0.0	9.999999999999999e-06
R406	BMX	180.0	5.0	1e-06
R406	CSNK2A1	64.0	6.4	1e-06
NVP-TAE684	ITK	34.0	0.1	1e-06
GSK461364	PGFRB	2900.0	9.8	9.999999999999999e-06
Barasertib	BLK	1500.0	9.6	9.999999999999999e-06
NVP-TAE684	KPCE	2000.0	16.0	1e-06
Crizotinib	TRKC	82.0	0.4	9.999999999999999e-06
R406	FLT3(D835Y)	0.4	0.0	1e-06
Canertinib	TESK1	3200.0	100.0	1e-06
R406	TLK1	490.0	10.0	1e-06
BI-2536	DMPK	2900.0	100.0	9.999999999999999e-06
Crizotinib	AXL	7.8	5.3	9.999999999999999e-06
Barasertib	MKNK2	1200.0	6.4	9.999999999999999e-06
NVP-TAE684	EPHB1	340.0	0.1	1e-06
GSK461364	KCC2D	620.0	7.3	9.999999999999999e-06
PLX-4720	AURKC	2500.0	100.0	9.999999999999999e-06
BI-2536	MERTK	3100.0	100.0	9.999999999999999e-06
NVP-TAE684	STK16	800.0	2.8	1e-06
R406	CAMK2A	1100.0	23.0	1e-06
R406	ERBB4	600.0	6.3	1e-06
R406	FGFR3	56.0	1.0	1e-06
BI-2536	FLT3(D835Y)	3000.0	100.0	9.999999999999999e-06
BI-2536	CAMKK2	23.0	1.9	9.999999999999999e-06
R406	JNK3	37.0	11.0	1e-06
Sorafenib	MERTK	3600.0	5.8	9.999999999999999e-06
PLX-4720	ABL1(M351T)-phosphorylated	2600.0	46.0	9.999999999999999e-06
Crizotinib	TAK1	1800.0	8.2	9.999999999999999e-06
R406	KPCD	4100.0	28.0	1e-06
Crizotinib	FLT3(R834Q)	3000.0	25.0	9.999999999999999e-06
R406	FGFR1	44.0	0.0	1e-06
R406	STK35	1400.0	12.0	1e-06
NVP-TAE684	LATS2	2000.0	17.0	1e-06
R406	MK12	390.0	7.5	1e-06
Barasertib	ABL1-nonphosphorylated	1500.0	3.4	9.999999999999999e-06
MLN8054	YES	260.0	3.9	9.999999999999999e-06
Sorafenib	CIT	6200.0	17.0	9.999999999999999e-06
R406	SRC	8.4	0.0	1e-06
GSK461364	NEK5	1100.0	25.0	9.999999999999999e-06
R406	SRPK3	400.0	9.4	1e-06
BMS345541	RSK1(Kin.Dom.2-C-terminal)	3300.0	46.0	9.999999999999999e-06
PLX-4720	BRAF	330.0	0.0	9.999999999999999e-06
MLN8054	ABL1(H396P)-nonphosphorylated	510.0	0.2	9.999999999999999e-06
Barasertib	EIF2AK1	1500.0	5.2	9.999999999999999e-06
NVP-TAE684	MST1	330.0	4.1	1e-06
Canertinib	DRAK2	7300.0	100.0	1e-06
Neratinib	EGFR(L747-E749del,A750P)	0.6	0.2	9.999999999999999e-06
R406	MARK1	270.0	2.0	1e-06
R406	PDPK1	120.0	4.6	1e-06
NVP-TAE684	EPHA4	910.0	30.0	1e-06
Neratinib	EGFR(L747-S752del,P753S)	0.9	0.6	9.999999999999999e-06
R406	KGP2	3600.0	6.8	1e-06
NVP-TAE684	EGFR(L747-E749del,A750P)	72.0	0.0	1e-06
Barasertib	FLT3(ITD)	140.0	2.5	9.999999999999999e-06
NVP-TAE684	STK36	1400.0	5.8	1e-06
Sorafenib	FLT3(D835H)	30.0	2.6	9.999999999999999e-06
PLX-4720	KIT	180.0	0.1	9.999999999999999e-06
R406	LIMK2	1400.0	9.6	1e-06
NVP-TAE684	EPHA7	200.0	0.4	1e-06
NVP-TAE684	FGFR2	250.0	1.0	1e-06
Sorafenib	KIT(V559D,T670I)	18.0	0.1	9.999999999999999e-06
GSK461364	IRAK1	6400.0	23.0	9.999999999999999e-06
Crizotinib	LCK	30.0	0.2	9.999999999999999e-06
Neratinib	ERBB3	7.7	0.1	9.999999999999999e-06
MLN8054	SRC	800.0	2.6	9.999999999999999e-06
NVP-TAE684	AURKB	150.0	1.0	1e-06
BI-2536	CAMK2A	1300.0	26.0	9.999999999999999e-06
BI-2536	ALK	160.0	6.2	9.999999999999999e-06
Neratinib	EGFR(L861Q)	0.4	0.1	9.999999999999999e-06
GSK461364	FLT3(ITD)	1500.0	31.0	9.999999999999999e-06
Canertinib	EGFR(G719C)	0.13	0.0	1e-06
BI-2536	EGFR(G719C)	630.0	23.0	9.999999999999999e-06
R406	RET(V804M)	3.1	0.0	1e-06
Barasertib	CDC2L1	1200.0	6.5	9.999999999999999e-06
NVP-TAE684	YANK2	24.0	0.2	1e-06
Barasertib	FLT3(N841I)	43.0	0.2	9.999999999999999e-06
Barasertib	LOK	2800.0	11.0	9.999999999999999e-06
MLN8054	AURKB	43.0	0.3	9.999999999999999e-06
Sorafenib	TAOK2	540.0	1.6	9.999999999999999e-06
BI-2536	TTK	2500.0	6.3	9.999999999999999e-06
Canertinib	PGFRB	7500.0	100.0	1e-06
Sorafenib	STK36	3800.0	23.0	9.999999999999999e-06
Pictilisib	PIK3CA	1.1	0.2	1.0000000000000002e-06
Barasertib	EGFR(L861Q)	510.0	11.0	9.999999999999999e-06
MLN8054	EGFR(L858R)	3200.0	29.0	9.999999999999999e-06
BI-2536	KPCD2	510.0	16.0	9.999999999999999e-06
Crizotinib	TRKA	95.0	0.1	9.999999999999999e-06
NVP-TAE684	EGFR(G719S)	1600.0	9.6	1e-06
Sorafenib	TNIK	7900.0	27.0	9.999999999999999e-06
Sorafenib	LCK	2700.0	5.2	9.999999999999999e-06
PLX-4720	KIT(V559D,V654A)	4800.0	19.0	9.999999999999999e-06
R406	BTK	190.0	2.0	1e-06
MLN8054	ABL1(H396P)-phosphorylated	940.0	8.8	9.999999999999999e-06
Pictilisib	JNK3	560.0	93.0	1.0000000000000002e-06
Crizotinib	M3K2	72.0	0.1	9.999999999999999e-06
GSK461364	GRK7	7500.0	33.0	9.999999999999999e-06
Crizotinib	M3K12	170.0	9.0	9.999999999999999e-06
Barasertib	EGFR(L747-S752del,P753S)	8800.0	56.0	9.999999999999999e-06
NVP-TAE684	CLK4	110.0	1.2	1e-06
Neratinib	CSK	550.0	13.0	9.999999999999999e-06
NVP-TAE684	FLT4	170.0	0.1	1e-06
Pictilisib	ICK	9300.0	100.0	1.0000000000000002e-06
R406	CHEK1	2500.0	14.0	1e-06
Crizotinib	ANKK1	780.0	4.2	9.999999999999999e-06
R406	BMPR1B	720.0	28.0	1e-06
PLX-4720	FLT3(D835H)	6100.0	43.0	9.999999999999999e-06
Neratinib	EGFR(G719S)	0.9	0.0	9.999999999999999e-06
Sorafenib	PLK4	4500.0	28.0	9.999999999999999e-06
R406	PKN2	2600.0	12.0	1e-06
Pictilisib	JAK1(JH2domain-pseudokinase)	430.0	18.0	1.0000000000000002e-06
Neratinib	SIK1	220.0	31.0	9.999999999999999e-06
R406	ACVR1	4800.0	100.0	1e-06
NVP-TAE684	BTK	23.0	0.0	1e-06
Sorafenib	ABL1(Q252H)-nonphosphorylated	130.0	1.3	9.999999999999999e-06
PLX-4720	KIT(V559D)	38.0	0.1	9.999999999999999e-06
Pictilisib	PIK3CG	48.0	3.5	1.0000000000000002e-06
R406	RET(M918T)	4.1	0.0	1e-06
R406	EPHB4	600.0	19.0	1e-06
BI-2536	FES	1900.0	100.0	9.999999999999999e-06
GSK461364	PIP5K1A	770.0	14.0	9.999999999999999e-06
Neratinib	STK33	940.0	42.0	9.999999999999999e-06
Crizotinib	ALK	3.3	8.6	9.999999999999999e-06
BMS345541	CDK7	680.0	6.3	9.999999999999999e-06
PLX-4720	ABL1(Q252H)-phosphorylated	4000.0	38.0	9.999999999999999e-06
BMS345541	CDK16	890.0	52.0	9.999999999999999e-06
Canertinib	MET	5600.0	100.0	1e-06
R406	MP2K1	320.0	15.0	1e-06
BI-2536	LTK	1200.0	24.0	9.999999999999999e-06
Pictilisib	PIK3CA(H1047Y)	4.1	0.0	1.0000000000000002e-06
Crizotinib	SRC	560.0	0.6	9.999999999999999e-06
R406	FER	130.0	1.7	1e-06
PLX-4720	LIMK1	2400.0	46.0	9.999999999999999e-06
Sorafenib	CDK3	3800.0	52.0	9.999999999999999e-06
Sorafenib	HIPK2	1700.0	4.4	9.999999999999999e-06
Pictilisib	RIOK2	670.0	67.0	1.0000000000000002e-06
Sorafenib	VGFR1	31.0	6.6	9.999999999999999e-06
R406	DRAK2	9.2	0.9	1e-06
Barasertib	LTK	3200.0	17.0	9.999999999999999e-06
BMS345541	CDK9	1900.0	35.0	9.999999999999999e-06
MLN8054	EPHB4	560.0	11.0	9.999999999999999e-06
Neratinib	YANK2	6400.0	73.0	9.999999999999999e-06
Neratinib	TNIK	140.0	6.0	9.999999999999999e-06
Barasertib	YES	3800.0	42.0	9.999999999999999e-06
R406	DAPK1	55.0	0.9	1e-06
Lapatinib	EGFR(E746-A750del)	8.6	0.0	9.999999999999999e-06
Crizotinib	MAP4K5	79.0	0.6	9.999999999999999e-06
MLN8054	FGR	220.0	7.6	9.999999999999999e-06
NVP-TAE684	LYN	280.0	5.0	1e-06
R406	ADCK4	64.0	0.0	1e-06
R406	KCC2D	3000.0	32.0	1e-06
NVP-TAE684	MUSK	260.0	0.4	1e-06
NVP-TAE684	KGP1	430.0	1.3	1e-06
MLN8054	EPHA5	1400.0	1.5	9.999999999999999e-06
PLX-4720	MP2K4	190.0	6.6	9.999999999999999e-06
GSK461364	TAOK3	1400.0	19.0	9.999999999999999e-06
Sorafenib	ABL1(F317I)-phosphorylated	4900.0	41.0	9.999999999999999e-06
NVP-TAE684	KCC2D	570.0	4.1	1e-06
NVP-TAE684	TGFBR2	250.0	2.7	1e-06
Sorafenib	MK09	7400.0	19.0	9.999999999999999e-06
Sorafenib	MAP4K4	4800.0	18.0	9.999999999999999e-06
NVP-TAE684	MP2K2	630.0	1.8	1e-06
MLN8054	EPHA7	1000.0	8.8	9.999999999999999e-06
NVP-TAE684	TIE1	15.0	0.0	1e-06
MLN8054	FAK2	2000.0	27.0	9.999999999999999e-06
Crizotinib	ABL1(Q252H)-nonphosphorylated	97.0	0.0	9.999999999999999e-06
R406	FYN	28.0	1.0	1e-06
R406	ROCK2	560.0	6.8	1e-06
Pictilisib	PIK3CA(I800L)	7.1	0.0	1.0000000000000002e-06
NVP-TAE684	GAK	5.3	0.1	1e-06
GSK461364	MAP3K1	1500.0	3.7	9.999999999999999e-06
MLN8054	EPHA2	370.0	4.9	9.999999999999999e-06
Sorafenib	FLT3(D835Y)	82.0	3.2	9.999999999999999e-06
Neratinib	SLK	66.0	1.4	9.999999999999999e-06
Canertinib	CSNK1E	420.0	100.0	1e-06
Canertinib	FRK	3400.0	100.0	1e-06
NVP-TAE684	CLK2	82.0	0.0	1e-06
NVP-TAE684	CSF1R	48.0	0.0	1e-06
BI-2536	KKCC1	22.0	1.9	9.999999999999999e-06
GSK461364	PIK3CG	1900.0	6.4	9.999999999999999e-06
NVP-TAE684	AURKA	44.0	0.0	1e-06
Canertinib	MAP3K4	8400.0	100.0	1e-06
Crizotinib	SNARK	120.0	5.5	9.999999999999999e-06
Canertinib	KIT(V559D,V654A)	7900.0	100.0	1e-06
NVP-TAE684	BMPR1B	0.9	1.2	1e-06
NVP-TAE684	MARK3	12.0	3.2	1e-06
Crizotinib	MST1R	25.0	0.3	9.999999999999999e-06
Barasertib	ABL1(E255K)-phosphorylated	9600.0	31.0	9.999999999999999e-06
GSK461364	ANKK1	6200.0	26.0	9.999999999999999e-06
R406	MST2	3000.0	32.0	1e-06
MLN8054	EPHB1	330.0	2.2	9.999999999999999e-06
Barasertib	KIT(V559D,V654A)	480.0	6.2	9.999999999999999e-06
R406	DAPK2	62.0	2.2	1e-06
PLX-4720	CLK2	2600.0	10.0	9.999999999999999e-06
Canertinib	BMX	2600.0	100.0	1e-06
R406	DDR2	43.0	2.3	1e-06
NVP-TAE684	TAOK3	44.0	0.1	1e-06
R406	EPHA2	140.0	5.1	1e-06
NVP-TAE684	STK35	260.0	16.0	1e-06
R406	TAOK1	490.0	8.7	1e-06
NVP-TAE684	CDK15	2100.0	16.0	1e-06
Canertinib	EGFR(E746-A750del)	0.26	0.3	1e-06
NVP-TAE684	HIPK1	4400.0	100.0	1e-06
MLN8054	IRAK3	1400.0	15.0	9.999999999999999e-06
Crizotinib	RET(M918T)	1300.0	17.0	9.999999999999999e-06
Crizotinib	FAK1	310.0	0.0	9.999999999999999e-06
Neratinib	MP2K1	14.0	0.4	9.999999999999999e-06
Canertinib	EGFR(L861Q)	0.22	0.0	1e-06
BMS345541	IKKA	1700.0	86.0	9.999999999999999e-06
PLX-4720	DCAMKL3	2500.0	26.0	9.999999999999999e-06
Lapatinib	PIK4CB	940.0	54.0	9.999999999999999e-06
NVP-TAE684	FGFR3	95.0	2.6	1e-06
Canertinib	EPHA4	3600.0	100.0	1e-06
Sorafenib	FGFR2	2700.0	14.0	9.999999999999999e-06
Neratinib	MP2K7	530.0	49.0	9.999999999999999e-06
MLN8054	LCK	590.0	1.6	9.999999999999999e-06
Barasertib	VGFR2	500.0	2.7	9.999999999999999e-06
BI-2536	MYLK	97.0	3.6	9.999999999999999e-06
NVP-TAE684	CAMK2A	980.0	1.2	1e-06
Sorafenib	ABL1(Q252H)-phosphorylated	5500.0	39.0	9.999999999999999e-06
Sorafenib	RAF1	230.0	0.1	9.999999999999999e-06
GSK461364	PIM1	250.0	3.0	9.999999999999999e-06
Crizotinib	ITK	2000.0	33.0	9.999999999999999e-06
R406	DRAK1	32.0	0.1	1e-06
Canertinib	RIPK2	300.0	29.0	1e-06
R406	YES	35.0	1.2	1e-06
Sorafenib	MLCK	9600.0	40.0	9.999999999999999e-06
Crizotinib	ACVR1	440.0	0.6	9.999999999999999e-06
PLX-4720	TESK1	1500.0	13.0	9.999999999999999e-06
BI-2536	AAK1	2800.0	100.0	9.999999999999999e-06
Sorafenib	CDKL3	490.0	0.6	9.999999999999999e-06
Barasertib	KIT(V559D,T670I)	7.9	0.0	9.999999999999999e-06
Lapatinib	RIPK2	3600.0	6.1	9.999999999999999e-06
NVP-TAE684	NEK2	1800.0	2.5	1e-06
Canertinib	LYN	810.0	100.0	1e-06
NVP-TAE684	RET(V804M)	140.0	0.5	1e-06
Crizotinib	ABL2	460.0	0.9	9.999999999999999e-06
Crizotinib	MUSK	230.0	0.3	9.999999999999999e-06
Crizotinib	TAOK2	900.0	0.9	9.999999999999999e-06
Crizotinib	SRPK1	1800.0	26.0	9.999999999999999e-06
NVP-TAE684	ACVR1B	97.0	0.1	1e-06
Sorafenib	CDK8	310.0	1.4	9.999999999999999e-06
PLX-4720	DDR1	2400.0	1.6	9.999999999999999e-06
BI-2536	JNK3	1100.0	100.0	9.999999999999999e-06
NVP-TAE684	ABL2	380.0	1.4	1e-06
PLX-4720	MAP4K5	3200.0	22.0	9.999999999999999e-06
Canertinib	ACVR1	1700.0	100.0	1e-06
Pictilisib	TYK2(JH2domain-pseudokinase)	1800.0	96.0	1.0000000000000002e-06
Crizotinib	IRAK3	31.0	1.0	9.999999999999999e-06
Crizotinib	DMPK	1400.0	1.6	9.999999999999999e-06
Sorafenib	RET(V804L)	39.0	0.1	9.999999999999999e-06
Pictilisib	MELK	5700.0	100.0	1.0000000000000002e-06
R406	FGFR4	350.0	0.3	1e-06
GSK461364	YSK4	2800.0	12.0	9.999999999999999e-06
R406	GSK3B	120.0	100.0	1e-06
NVP-TAE684	EPHA6	120.0	3.1	1e-06
Crizotinib	DDR1	510.0	0.4	9.999999999999999e-06
NVP-TAE684	KIT(V559D,T670I)	130.0	1.0	1e-06
BMS345541	DCAMKL3	1700.0	76.0	9.999999999999999e-06
Sorafenib	FLT3(R834Q)	17.0	50.0	9.999999999999999e-06
MLN8054	TIE1	1600.0	14.0	9.999999999999999e-06
GSK461364	DAPK2	2900.0	15.0	9.999999999999999e-06
BI-2536	DAPK3	130.0	3.6	9.999999999999999e-06
PLX-4720	FLT3(N841I)	3900.0	28.0	9.999999999999999e-06
Neratinib	MLK3	5800.0	85.0	9.999999999999999e-06
NVP-TAE684	FLT3(ITD)	8.6	0.0	1e-06
MLN8054	AURKC	26.0	20.0	9.999999999999999e-06
Sorafenib	LIMK1	1600.0	30.0	9.999999999999999e-06
R406	PAK7	69.0	0.7	1e-06
Crizotinib	INSR	340.0	0.2	9.999999999999999e-06
R406	TNK1	25.0	0.1	1e-06
NVP-TAE684	DMPK	2100.0	1.8	1e-06
PLX-4720	SRMS	21.0	0.1	9.999999999999999e-06
Canertinib	LOK	1900.0	100.0	1e-06
PLX-4720	ABL1-phosphorylated	2300.0	43.0	9.999999999999999e-06
MLN8054	FGFR3(G697C)	1300.0	12.0	9.999999999999999e-06
R406	EPHA5	860.0	4.6	1e-06
Canertinib	EPHB2	2700.0	100.0	1e-06
Canertinib	ADCK3	1500.0	100.0	1e-06
Barasertib	FLT3(D835Y)	670.0	21.0	9.999999999999999e-06
NVP-TAE684	BRSK1	310.0	1.2	1e-06
Crizotinib	KPCD3	510.0	3.0	9.999999999999999e-06
Canertinib	RET(M918T)	840.0	100.0	1e-06
Crizotinib	EPHA2	100.0	1.5	9.999999999999999e-06
PLX-4720	SIK1	520.0	2.6	9.999999999999999e-06
GSK461364	RSK4(Kin.Dom.1-N-terminal)	350.0	0.6	9.999999999999999e-06
PLX-4720	AURKB	2300.0	29.0	9.999999999999999e-06
NVP-TAE684	FGR	120.0	2.8	1e-06
GSK461364	PIK3C2B	2800.0	14.0	9.999999999999999e-06
BI-2536	PLK1	0.2	19.0	9.999999999999999e-06
MLN8054	DRAK2	8.1	8.6	9.999999999999999e-06
MLN8054	DDR1	4200.0	1.2	9.999999999999999e-06
Sorafenib	FYN	8400.0	48.0	9.999999999999999e-06
Neratinib	CAMK1D	5600.0	76.0	9.999999999999999e-06
R406	PAK3	690.0	2.2	1e-06
Crizotinib	RIPK4	2100.0	8.2	9.999999999999999e-06
Crizotinib	NIM1	4600.0	12.0	9.999999999999999e-06
Sorafenib	CSF1R	28.0	0.1	9.999999999999999e-06
Crizotinib	ABL1(Y253F)-phosphorylated	74.0	0.1	9.999999999999999e-06
R406	CLK2	1600.0	9.1	1e-06
Barasertib	ABL1(F317I)-nonphosphorylated	3800.0	15.0	9.999999999999999e-06
R406	INSR	1100.0	16.0	1e-06
Crizotinib	M4K1	39.0	4.6	9.999999999999999e-06
R406	PGFRB	3.3	0.0	1e-06
Sorafenib	BRAF	540.0	1.2	9.999999999999999e-06
Neratinib	MAP3K4	39.0	4.8	9.999999999999999e-06
Canertinib	BIKE	3800.0	100.0	1e-06
R406	MLK1	4.3	0.2	1e-06
PLX-4720	RIOK2	770.0	3.0	9.999999999999999e-06
PLX-4720	MINK	7100.0	28.0	9.999999999999999e-06
BMS345541	KPCD1	4600.0	47.0	9.999999999999999e-06
Neratinib	KPCD1	820.0	74.0	9.999999999999999e-06
NVP-TAE684	YANK3	55.0	3.1	1e-06
BI-2536	DCLK1	5900.0	5.4	9.999999999999999e-06
BI-2536	KCC2D	2400.0	100.0	9.999999999999999e-06
NVP-TAE684	SNARK	1.2	0.0	1e-06
Crizotinib	ABL1(E255K)-phosphorylated	170.0	0.2	9.999999999999999e-06
Pictilisib	PIK3CA(Q546K)	1.7	0.1	1.0000000000000002e-06
Neratinib	LCK	120.0	3.7	9.999999999999999e-06
NVP-TAE684	CHK2	72.0	0.0	1e-06
NVP-TAE684	MK12	9400.0	100.0	1e-06
NVP-TAE684	RET	150.0	0.0	1e-06
Sorafenib	LIMK2	9600.0	57.0	9.999999999999999e-06
Lapatinib	MP2K7	4400.0	35.0	9.999999999999999e-06
Sorafenib	FLT3(K663Q)	4.5	0.5	9.999999999999999e-06
Barasertib	LCK	380.0	2.2	9.999999999999999e-06
Neratinib	ERBB2	6.0	0.0	9.999999999999999e-06
R406	YSK1	9200.0	12.0	1e-06
R406	PAK1	260.0	10.0	1e-06
GSK461364	FLT3	620.0	11.0	9.999999999999999e-06
NVP-TAE684	MELK	99.0	1.0	1e-06
Crizotinib	ABL1(Q252H)-phosphorylated	100.0	0.1	9.999999999999999e-06
Crizotinib	MAP3K3	110.0	0.2	9.999999999999999e-06
NVP-TAE684	FER	1.4	0.1	1e-06
NVP-TAE684	IGF1R	2.7	0.0	1e-06
Barasertib	ABL1(F317L)-phosphorylated	2300.0	10.0	9.999999999999999e-06
Canertinib	ALK	7700.0	100.0	1e-06
BI-2536	PIK3CD	7600.0	100.0	9.999999999999999e-06
NVP-TAE684	KGP2	240.0	7.6	1e-06
PLX-4720	PGFRB	200.0	0.0	9.999999999999999e-06
BI-2536	KPCD3	350.0	10.0	9.999999999999999e-06
Crizotinib	EPHA5	1000.0	1.8	9.999999999999999e-06
Crizotinib	MET	2.1	6.2	9.999999999999999e-06
R406	ANKK1	330.0	13.0	1e-06
PLX-4720	ABL1(F317L)-phosphorylated	5700.0	32.0	9.999999999999999e-06
Pictilisib	PIK3C2B	130.0	18.0	1.0000000000000002e-06
NVP-TAE684	EGFR(G719C)	2000.0	9.9	1e-06
R406	SIK1	53.0	0.1	1e-06
Crizotinib	MP2K3	3300.0	42.0	9.999999999999999e-06
Neratinib	WEE2	1300.0	98.0	9.999999999999999e-06
Sorafenib	ABL1(T315I)-phosphorylated	1500.0	28.0	9.999999999999999e-06
Crizotinib	EPHA7	470.0	0.3	9.999999999999999e-06
Crizotinib	LIMK2	690.0	4.6	9.999999999999999e-06
R406	MST1R	470.0	0.0	1e-06
Neratinib	INSR	3000.0	46.0	9.999999999999999e-06
R406	BRAF	240.0	24.0	1e-06
R406	TRKA	170.0	4.5	1e-06
Barasertib	KIT(D816H)	2900.0	34.0	9.999999999999999e-06
Barasertib	RET(M918T)	120.0	0.2	9.999999999999999e-06
Neratinib	MAP4K2	220.0	5.2	9.999999999999999e-06
NVP-TAE684	DCAMKL2	16.0	0.0	1e-06
Pictilisib	CAMK1G	6800.0	100.0	1.0000000000000002e-06
Canertinib	MKNK2	1800.0	100.0	1e-06
Barasertib	EGFR(L747-E749del,A750P)	2900.0	33.0	9.999999999999999e-06
Neratinib	MST3	6.5	0.4	9.999999999999999e-06
Canertinib	JNK3	5500.0	100.0	1e-06
Crizotinib	ROCK2	3300.0	8.0	9.999999999999999e-06
Canertinib	KIT(V559D,T670I)	1900.0	100.0	1e-06
NVP-TAE684	PKAC-alpha	4000.0	11.0	1e-06
NVP-TAE684	LIMK1	1100.0	2.2	1e-06
R406	PTK6	360.0	5.6	1e-06
Canertinib	CIT	1300.0	100.0	1e-06
PLX-4720	BMPR1B	3100.0	13.0	9.999999999999999e-06
Crizotinib	YSK4	980.0	2.4	9.999999999999999e-06
Neratinib	M3K2	450.0	24.0	9.999999999999999e-06
Canertinib	ADCK4	3400.0	100.0	1e-06
Neratinib	MAP4K5	0.7	0.9	9.999999999999999e-06
Pictilisib	JNK1	1500.0	71.0	1.0000000000000002e-06
BI-2536	KC1G2	5700.0	100.0	9.999999999999999e-06
Crizotinib	MST4	2800.0	13.0	9.999999999999999e-06
Crizotinib	SgK110	240.0	3.4	9.999999999999999e-06
R406	MP2K3	100.0	5.4	1e-06
PLX-4720	KIT(L576P)	400.0	6.4	9.999999999999999e-06
Pictilisib	PIK3CA(E542K)	1.5	0.0	1.0000000000000002e-06
Neratinib	FLT3(D835H)	4600.0	94.0	9.999999999999999e-06
Sorafenib	MK11	230.0	0.2	9.999999999999999e-06
MLN8054	CLK3	2300.0	14.0	9.999999999999999e-06
Neratinib	M3K13	740.0	86.0	9.999999999999999e-06
Sorafenib	KIT(A829P)	20.0	59.0	9.999999999999999e-06
R406	CIT	440.0	4.7	1e-06
PLX-4720	MYLK4	3400.0	15.0	9.999999999999999e-06
Neratinib	DRAK2	1100.0	46.0	9.999999999999999e-06
Sorafenib	DDR2	6.6	14.0	9.999999999999999e-06
Crizotinib	DCLK1	330.0	2.0	9.999999999999999e-06
R406	SRPK1	590.0	0.5	1e-06
Canertinib	FLT3(D835H)	1200.0	100.0	1e-06
GSK461364	MERTK	4600.0	24.0	9.999999999999999e-06
BI-2536	STK33	1100.0	14.0	9.999999999999999e-06
BMS345541	ERK5	620.0	0.7	9.999999999999999e-06
Barasertib	ABL1(F317I)-phosphorylated	4600.0	39.0	9.999999999999999e-06
R406	FLT3(N841I)	1.5	0.8	1e-06
PLX-4720	HIPK1	5500.0	36.0	9.999999999999999e-06
Canertinib	LTK	5100.0	100.0	1e-06
R406	NEK1	170.0	1.2	1e-06
NVP-TAE684	BLK	130.0	0.1	1e-06
NVP-TAE684	TIE2	46.0	0.0	1e-06
NVP-TAE684	YSK1	7700.0	100.0	1e-06
Crizotinib	TYK2(JH2domain-pseudokinase)	2000.0	2.3	9.999999999999999e-06
Crizotinib	DYRK2	4000.0	9.6	9.999999999999999e-06
R406	ULK1	14.0	0.2	1e-06
Sorafenib	ABL1(T315I)-nonphosphorylated	590.0	0.4	9.999999999999999e-06
Lapatinib	ERBB3	5500.0	37.0	9.999999999999999e-06
MLN8054	MERTK	730.0	3.0	9.999999999999999e-06
Neratinib	SRC	4100.0	82.0	9.999999999999999e-06
BMS345541	TYK2(JH2domain-pseudokinase)	2000.0	15.0	9.999999999999999e-06
NVP-TAE684	NEK7	2300.0	3.8	1e-06
NVP-TAE684	KPCD2	160.0	0.1	1e-06
GSK461364	DAPK1	1400.0	8.4	9.999999999999999e-06
Canertinib	TXK	700.0	30.0	1e-06
Neratinib	MST1R	8400.0	100.0	9.999999999999999e-06
R406	MARK4	89.0	0.7	1e-06
R406	EGFR(S752-I759del)	450.0	4.8	1e-06
Neratinib	M4K1	93.0	45.0	9.999999999999999e-06
R406	EGFR(L858R)	250.0	2.3	1e-06
NVP-TAE684	FGFR4	110.0	0.0	1e-06
Sorafenib	EPHA3	1900.0	5.6	9.999999999999999e-06
Crizotinib	CAMKK2	1500.0	8.8	9.999999999999999e-06
Sorafenib	MK14	370.0	0.2	9.999999999999999e-06
Barasertib	PGFRA	38.0	0.0	9.999999999999999e-06
Sorafenib	HIPK4	3.3	12.0	9.999999999999999e-06
Sorafenib	EPHA5	3500.0	30.0	9.999999999999999e-06
MLN8054	EPHA4	420.0	11.0	9.999999999999999e-06
Neratinib	YES	240.0	26.0	9.999999999999999e-06
BI-2536	CAMK1D	5400.0	100.0	9.999999999999999e-06
Pictilisib	HIPK2	520.0	61.0	1.0000000000000002e-06
Crizotinib	TNK1	320.0	7.1	9.999999999999999e-06
Sorafenib	FRK	510.0	6.6	9.999999999999999e-06
Barasertib	FLT3(D835H)	210.0	4.0	9.999999999999999e-06
Sorafenib	RET	13.0	0.1	9.999999999999999e-06
PLX-4720	FES	3600.0	55.0	9.999999999999999e-06
NVP-TAE684	JNK3	67.0	2.6	1e-06
R406	MYLK4	810.0	4.4	1e-06
PLX-4720	DYRK2	2700.0	100.0	9.999999999999999e-06
Canertinib	MKNK1	260.0	34.0	1e-06
Barasertib	EGFR(L747-T751del,Sins)	3500.0	37.0	9.999999999999999e-06
MLN8054	TEC	730.0	2.0	9.999999999999999e-06
PLX-4720	ABL1(Q252H)-nonphosphorylated	200.0	1.0	9.999999999999999e-06
Crizotinib	FES	450.0	2.7	9.999999999999999e-06
R406	M4K1	1400.0	14.0	1e-06
PLX-4720	EPHB6	860.0	3.6	9.999999999999999e-06
NVP-TAE684	ZAP70	1600.0	10.0	1e-06
R406	NEK2	260.0	6.1	1e-06
Canertinib	PTK6	3800.0	100.0	1e-06
NVP-TAE684	M4K1	140.0	3.2	1e-06
Pictilisib	PIK3CA(E545A)	0.9	0.0	1.0000000000000002e-06
Neratinib	SIK2	3300.0	58.0	9.999999999999999e-06
Barasertib	EGFR(T790M)	1500.0	22.0	9.999999999999999e-06
Neratinib	WEE1	4100.0	57.0	9.999999999999999e-06
BI-2536	DAPK1	540.0	5.4	9.999999999999999e-06
PLX-4720	CDK11	700.0	0.8	9.999999999999999e-06
R406	TGFBR2	330.0	3.6	1e-06
Sorafenib	EPHA7	5300.0	25.0	9.999999999999999e-06
Canertinib	SRC	1100.0	100.0	1e-06
Neratinib	BLK	85.0	3.0	9.999999999999999e-06
Crizotinib	FLT3(N841I)	860.0	2.0	9.999999999999999e-06
R406	PIP5K1A	1900.0	4.3	1e-06
Neratinib	CHEK1	5700.0	65.0	9.999999999999999e-06
Sorafenib	FLT4	95.0	0.0	9.999999999999999e-06
Pictilisib	FLT3(K663Q)	2600.0	100.0	1.0000000000000002e-06
MLN8054	BLK	68.0	0.7	9.999999999999999e-06
Canertinib	EPHA1	2500.0	100.0	1e-06
NVP-TAE684	MRCKB	4800.0	25.0	1e-06
Canertinib	DDR1	400.0	100.0	1e-06
R406	IGF1R	1300.0	2.4	1e-06
NVP-TAE684	EGFR(L861Q)	98.0	0.2	1e-06
NVP-TAE684	LTK	1.0	0.0	1e-06
NVP-TAE684	PCTK2	810.0	9.9	1e-06
NVP-TAE684	MST3	2900.0	24.0	1e-06
Sorafenib	LOK	150.0	0.0	9.999999999999999e-06
Barasertib	AURKB	4.6	0.2	9.999999999999999e-06
BI-2536	KPCD1	320.0	7.0	9.999999999999999e-06
Sorafenib	ABL2	2900.0	35.0	9.999999999999999e-06
Sorafenib	RSK4(Kin.Dom.2-C-terminal)	7500.0	38.0	9.999999999999999e-06
Crizotinib	ABL1(F317I)-phosphorylated	3200.0	13.0	9.999999999999999e-06
R406	CAMK2G	920.0	100.0	1e-06
NVP-TAE684	KIT(D816V)	26.0	3.1	1e-06
PLX-4720	FGR	62.0	8.4	9.999999999999999e-06
BI-2536	CSNK1G3	2400.0	100.0	9.999999999999999e-06
PLX-4720	KC1G2	4100.0	39.0	9.999999999999999e-06
R406	FAK1	250.0	0.4	1e-06
Pictilisib	MTOR	200.0	13.0	1.0000000000000002e-06
Barasertib	RIPK2	1800.0	17.0	9.999999999999999e-06
Sorafenib	RIPK2	1300.0	18.0	9.999999999999999e-06
Barasertib	ERBB2	4300.0	13.0	9.999999999999999e-06
GSK461364	DAPK3	5500.0	15.0	9.999999999999999e-06
Canertinib	ERBB4	6.5	0.8	1e-06
NVP-TAE684	VGFR1	550.0	2.8	1e-06
Sorafenib	FGR	7800.0	53.0	9.999999999999999e-06
R406	RAF1	840.0	17.0	1e-06
PLX-4720	VGFR2	2100.0	30.0	9.999999999999999e-06
Crizotinib	RIOK1	6100.0	3.4	9.999999999999999e-06
Neratinib	KPCD2	1100.0	50.0	9.999999999999999e-06
Crizotinib	TIE1	110.0	4.4	9.999999999999999e-06
NVP-TAE684	FLT3(D835H)	4.9	0.1	1e-06
Canertinib	FLT3(D835Y)	730.0	100.0	1e-06
Neratinib	YSK4	16.0	0.5	9.999999999999999e-06
Sorafenib	FLT3(N841I)	11.0	0.3	9.999999999999999e-06
Crizotinib	RIPK1	1600.0	5.0	9.999999999999999e-06
Neratinib	M4K3	7.7	2.1	9.999999999999999e-06
R406	JNK1	38.0	0.0	1e-06
NVP-TAE684	ULK3	11.0	0.0	1e-06
Crizotinib	RET(V804L)	2100.0	30.0	9.999999999999999e-06
NVP-TAE684	ERK8	210.0	0.3	1e-06
R406	ALK	240.0	0.2	1e-06
MLN8054	ABL1(T315I)-phosphorylated	2800.0	11.0	9.999999999999999e-06
Canertinib	FLT3(ITD)	3000.0	100.0	1e-06
NVP-TAE684	PIP5K1A	9700.0	1.3	1e-06
GSK461364	FLT3(K663Q)	650.0	14.0	9.999999999999999e-06
Crizotinib	ROCK1	3700.0	4.0	9.999999999999999e-06
Crizotinib	LYN	940.0	13.0	9.999999999999999e-06
NVP-TAE684	EGFR(E746-A750del)	81.0	0.0	1e-06
R406	SYK	19.0	0.3	1e-06
GSK461364	LOK	69.0	0.0	9.999999999999999e-06
Sorafenib	HIPK3	440.0	0.6	9.999999999999999e-06
Crizotinib	KPCD1	990.0	2.4	9.999999999999999e-06
Barasertib	IRAK3	7900.0	37.0	9.999999999999999e-06
Crizotinib	ABL1(H396P)-nonphosphorylated	33.0	0.0	9.999999999999999e-06
GSK461364	CDK7	7700.0	33.0	9.999999999999999e-06
GSK461364	PIP5K2B	4500.0	5.8	9.999999999999999e-06
GSK461364	PIP5K1C	6700.0	18.0	9.999999999999999e-06
Crizotinib	FGFR3(G697C)	3500.0	27.0	9.999999999999999e-06
BMS345541	DYRK2	2100.0	8.8	9.999999999999999e-06
Neratinib	EPHB6	2800.0	83.0	9.999999999999999e-06
NVP-TAE684	KCC4	30.0	0.5	1e-06
Barasertib	TIE2	1900.0	13.0	9.999999999999999e-06
NVP-TAE684	IRAK3	160.0	0.2	1e-06
Lapatinib	EGFR(S752-I759del)	4.2	0.8	9.999999999999999e-06
PLX-4720	ABL1(F317I)-phosphorylated	5000.0	43.0	9.999999999999999e-06
Crizotinib	BIKE	740.0	0.5	9.999999999999999e-06
PLX-4720	ABL2	2700.0	36.0	9.999999999999999e-06
GSK461364	GCN2(Kin.Dom.2,S808G)	4100.0	29.0	9.999999999999999e-06
Crizotinib	JAK1(JH1domain-catalytic)	330.0	0.5	9.999999999999999e-06
Neratinib	M3K12	370.0	36.0	9.999999999999999e-06
NVP-TAE684	DRAK2	7100.0	100.0	1e-06
R406	LCK	30.0	0.1	1e-06
NVP-TAE684	CLK1	12.0	0.4	1e-06
PLX-4720	HIPK4	5400.0	34.0	9.999999999999999e-06
BMS345541	ERK8	4500.0	19.0	9.999999999999999e-06
Barasertib	KIT(A829P)	600.0	50.0	9.999999999999999e-06
Sorafenib	FGFR3	4200.0	31.0	9.999999999999999e-06
R406	CDK7	7700.0	23.0	1e-06
Canertinib	TEC	1500.0	100.0	1e-06
R406	PAK4	96.0	3.4	1e-06
Crizotinib	BTK	7800.0	22.0	9.999999999999999e-06
GSK461364	CSNK2A2	990.0	4.6	9.999999999999999e-06
PLX-4720	HCK	2700.0	19.0	9.999999999999999e-06
NVP-TAE684	EGFR(L858R)	46.0	0.1	1e-06
Neratinib	SNARK	140.0	8.8	9.999999999999999e-06
Crizotinib	INSRR	600.0	0.3	9.999999999999999e-06
MLN8054	TIE2	300.0	3.0	9.999999999999999e-06
Canertinib	ERBB2	56.0	9.6	1e-06
Crizotinib	TXK	850.0	5.9	9.999999999999999e-06
Sorafenib	TNK1	2300.0	37.0	9.999999999999999e-06
R406	LTK	800.0	1.4	1e-06
GSK461364	PLK2	500.0	2.6	9.999999999999999e-06
Neratinib	FLT3(N841I)	6400.0	64.0	9.999999999999999e-06
Crizotinib	DCAMKL2	370.0	1.2	9.999999999999999e-06
Barasertib	DDR2	6600.0	27.0	9.999999999999999e-06
Neratinib	EGFR(T790M)	1.5	0.2	9.999999999999999e-06
NVP-TAE684	ACVR2A	2200.0	12.0	1e-06
Pictilisib	PLK4	2600.0	95.0	1.0000000000000002e-06
Crizotinib	ABL1(F317L)-phosphorylated	590.0	0.0	9.999999999999999e-06
Neratinib	MP2K5	63.0	1.8	9.999999999999999e-06
R406	FLT3(K663Q)	0.7	0.1	1e-06
R406	IKKA	120.0	2.2	1e-06
NVP-TAE684	LIMK2	1100.0	6.5	1e-06
Neratinib	MST4	7.4	2.0	9.999999999999999e-06
PLX-4720	ABL1(E255K)-phosphorylated	4500.0	46.0	9.999999999999999e-06
Sorafenib	SLK	1000.0	15.0	9.999999999999999e-06
Crizotinib	STK35	610.0	3.2	9.999999999999999e-06
PLX-4720	CAMK1	1900.0	14.0	9.999999999999999e-06
NVP-TAE684	PHKG1	17.0	0.1	1e-06
Crizotinib	ZAP70	4200.0	29.0	9.999999999999999e-06
Crizotinib	EGFR(G719C)	2700.0	71.0	9.999999999999999e-06
Pictilisib	RSK2(Kin.Dom.1-N-terminal)	3000.0	80.0	1.0000000000000002e-06
Canertinib	YES	1600.0	100.0	1e-06
R406	EPHA6	120.0	5.2	1e-06
R406	SIK2	78.0	5.5	1e-06
R406	MP2K4	200.0	6.0	1e-06
Lapatinib	EGFR(L861Q)	1.2	0.0	9.999999999999999e-06
NVP-TAE684	CSNK2A2	9600.0	100.0	1e-06
NVP-TAE684	EPHA5	3700.0	21.0	1e-06
NVP-TAE684	SIK1	15.0	0.0	1e-06
NVP-TAE684	RIOK3	3500.0	3.2	1e-06
Crizotinib	SRPK3	8200.0	15.0	9.999999999999999e-06
NVP-TAE684	PKAC-beta	4100.0	9.9	1e-06
Pictilisib	CSNK2A2	2400.0	95.0	1.0000000000000002e-06
R406	PIP5K2B	1200.0	8.2	1e-06
Crizotinib	ULK3	6700.0	8.8	9.999999999999999e-06
Sorafenib	TTK	3500.0	15.0	9.999999999999999e-06
Barasertib	EGFR(G719S)	170.0	1.8	9.999999999999999e-06
Crizotinib	IGF1R	780.0	0.9	9.999999999999999e-06
MLN8054	LYN	1400.0	25.0	9.999999999999999e-06
Crizotinib	BMX	3600.0	28.0	9.999999999999999e-06
R406	MK09	47.0	11.0	1e-06
R406	ERK8	640.0	2.7	1e-06
Barasertib	MAP4K5	160.0	1.0	9.999999999999999e-06
NVP-TAE684	RET(M918T)	140.0	0.1	1e-06
PLX-4720	LCK	1800.0	3.2	9.999999999999999e-06
NVP-TAE684	MK09	280.0	12.0	1e-06
BI-2536	HIPK1	4100.0	100.0	9.999999999999999e-06
Lapatinib	PIK3C2G	7500.0	100.0	9.999999999999999e-06
MLN8054	VGFR1	1000.0	12.0	9.999999999999999e-06
NVP-TAE684	PTK6	36.0	0.2	1e-06
Lapatinib	EGFR(L747-E749del,A750P)	2.2	0.0	9.999999999999999e-06
Sorafenib	MUSK	130.0	0.1	9.999999999999999e-06
Crizotinib	RIPK5	450.0	1.6	9.999999999999999e-06
GSK461364	PLK3	740.0	3.6	9.999999999999999e-06
Barasertib	S6K1	2800.0	13.0	9.999999999999999e-06
Pictilisib	AAK1	9100.0	93.0	1.0000000000000002e-06
Neratinib	HIPK4	1500.0	42.0	9.999999999999999e-06
Sorafenib	TRKA	6300.0	16.0	9.999999999999999e-06
GSK461364	BRSK2	8300.0	52.0	9.999999999999999e-06
PLX-4720	BLK	1100.0	1.7	9.999999999999999e-06
BMS345541	YSK4	260.0	16.0	9.999999999999999e-06
NVP-TAE684	MST4	510.0	27.0	1e-06
Pictilisib	TTK	4300.0	93.0	1.0000000000000002e-06
BMS345541	RSK4(Kin.Dom.2-C-terminal)	6700.0	40.0	9.999999999999999e-06
Neratinib	FAK1	1900.0	65.0	9.999999999999999e-06
Crizotinib	ABL1-phosphorylated	110.0	0.0	9.999999999999999e-06
GSK461364	NEK1	1800.0	41.0	9.999999999999999e-06
NVP-TAE684	CLK3	210.0	3.0	1e-06
NVP-TAE684	MP2K4	150.0	1.6	1e-06
BI-2536	PHKG2	1600.0	20.0	9.999999999999999e-06
NVP-TAE684	MAP4K4	970.0	5.4	1e-06
PLX-4720	OSR1	3900.0	24.0	9.999999999999999e-06
Crizotinib	EPHA3	700.0	11.0	9.999999999999999e-06
NVP-TAE684	AMPK-alpha2	49.0	0.2	1e-06
R406	ITK	400.0	4.2	1e-06
BI-2536	TAOK3	1700.0	100.0	9.999999999999999e-06
BI-2536	FAK2	310.0	20.0	9.999999999999999e-06
Lapatinib	SLK	3300.0	18.0	9.999999999999999e-06
Canertinib	HCK	4200.0	100.0	1e-06
R406	PAK6	310.0	4.1	1e-06
Sorafenib	AURKC	210.0	100.0	9.999999999999999e-06
PLX-4720	STK36	2900.0	18.0	9.999999999999999e-06
Crizotinib	S6K1	640.0	1.8	9.999999999999999e-06
PLX-4720	CSK	2200.0	2.7	9.999999999999999e-06
Sorafenib	PGFRB	37.0	0.0	9.999999999999999e-06
PLX-4720	PLK4	3500.0	27.0	9.999999999999999e-06
BMS345541	CDC2L2	390.0	1.0	9.999999999999999e-06
R406	AMPK-alpha2	750.0	2.4	1e-06
Barasertib	EGFR(G719C)	120.0	1.2	9.999999999999999e-06
Crizotinib	EPHA6	65.0	0.7	9.999999999999999e-06
PLX-4720	ABL1-nonphosphorylated	460.0	1.2	9.999999999999999e-06
PLX-4720	KIT(A829P)	5800.0	67.0	9.999999999999999e-06
NVP-TAE684	M4K3	65.0	2.5	1e-06
R406	STK16	1.7	0.2	1e-06
GSK461364	RIOK1	3400.0	4.4	9.999999999999999e-06
R406	NEK6	6.3	0.0	1e-06
BI-2536	CIT	5200.0	100.0	9.999999999999999e-06
Crizotinib	AURKB	76.0	0.3	9.999999999999999e-06
BMS345541	KIT(L576P)	3900.0	28.0	9.999999999999999e-06
NVP-TAE684	KIT(V559D,V654A)	1200.0	7.4	1e-06
NVP-TAE684	EPHA3	4000.0	100.0	1e-06
BI-2536	SLK	4100.0	3.0	9.999999999999999e-06
NVP-TAE684	NEK6	1300.0	1.8	1e-06
Crizotinib	FLT3(D835H)	500.0	6.8	9.999999999999999e-06
Neratinib	PAK2	79.0	34.0	9.999999999999999e-06
Barasertib	FLT3(K663Q)	3.9	1.0	9.999999999999999e-06
Crizotinib	PIP5K1A	3200.0	0.1	9.999999999999999e-06
R406	EPHB1	390.0	0.2	1e-06
Barasertib	ANKK1	1500.0	11.0	9.999999999999999e-06
NVP-TAE684	EGFR	180.0	0.1	1e-06
Crizotinib	EPHB4	570.0	4.8	9.999999999999999e-06
Pictilisib	FLT3	2600.0	67.0	1.0000000000000002e-06
GSK461364	GRK4	2800.0	16.0	9.999999999999999e-06
R406	SNARK	65.0	3.0	1e-06
MLN8054	PLK4	410.0	14.0	9.999999999999999e-06
Canertinib	TGFBR1	9600.0	100.0	1e-06
Barasertib	LYN	1600.0	18.0	9.999999999999999e-06
Neratinib	EGFR(L747-T751del,Sins)	1.0	0.3	9.999999999999999e-06
NVP-TAE684	PAK4	2000.0	9.6	1e-06
Canertinib	FYN	5300.0	100.0	1e-06
NVP-TAE684	ACVRL1	57.0	1.7	1e-06
Barasertib	MUSK	1500.0	3.3	9.999999999999999e-06
NVP-TAE684	CDK7	190.0	0.2	1e-06
Neratinib	RIPK5	6400.0	69.0	9.999999999999999e-06
NVP-TAE684	MST1R	610.0	3.0	1e-06
PLX-4720	STK16	1900.0	18.0	9.999999999999999e-06
Crizotinib	LIMK1	830.0	2.7	9.999999999999999e-06
MLN8054	FLT4	3100.0	18.0	9.999999999999999e-06
Sorafenib	VGFR2	59.0	0.8	9.999999999999999e-06
Canertinib	MP2K1	1800.0	100.0	1e-06
PLX-4720	TNIK	2500.0	24.0	9.999999999999999e-06
Sorafenib	ABL1-phosphorylated	1400.0	25.0	9.999999999999999e-06
R406	VGFR2	40.0	0.2	1e-06
R406	PLK3	5.1	0.0	1e-06
Barasertib	CSK	3800.0	24.0	9.999999999999999e-06
Barasertib	CDK7	6200.0	15.0	9.999999999999999e-06
PLX-4720	MP2K5	0.2	0.2	9.999999999999999e-06
Pictilisib	EPHB6	1600.0	57.0	1.0000000000000002e-06
R406	ACVR1B	1100.0	24.0	1e-06
NVP-TAE684	PGFRB	150.0	0.3	1e-06
R406	STK33	970.0	1.6	1e-06
Sorafenib	MLTK	6.3	4.2	9.999999999999999e-06
Crizotinib	NEK9	790.0	6.2	9.999999999999999e-06
PLX-4720	FLT3	1300.0	14.0	9.999999999999999e-06
NVP-TAE684	TAK1	160.0	2.2	1e-06
Canertinib	MK09	1100.0	100.0	1e-06
R406	GCN2(Kin.Dom.2,S808G)	3.3	0.2	1e-06
MLN8054	ABL1(Q252H)-phosphorylated	1300.0	7.8	9.999999999999999e-06
Barasertib	RET(V804L)	140.0	2.0	9.999999999999999e-06
Pictilisib	PCTK3	4600.0	94.0	1.0000000000000002e-06
Neratinib	STK36	5300.0	69.0	9.999999999999999e-06
Sorafenib	EPHA4	3000.0	42.0	9.999999999999999e-06
NVP-TAE684	AAK1	470.0	2.8	1e-06
Canertinib	TIE1	2200.0	100.0	1e-06
MLN8054	FGFR1	2400.0	14.0	9.999999999999999e-06
Crizotinib	PLK4	60.0	0.1	9.999999999999999e-06
NVP-TAE684	SRPK1	4800.0	2.2	1e-06
Crizotinib	ABL1(M351T)-phosphorylated	97.0	1.6	9.999999999999999e-06
R406	CLK3	1900.0	5.3	1e-06
Sorafenib	CDK5	8300.0	39.0	9.999999999999999e-06
R406	CSF1R	31.0	0.0	1e-06
Crizotinib	KIT(V559D,T670I)	800.0	7.0	9.999999999999999e-06
NVP-TAE684	SIK2	17.0	7.5	1e-06
Neratinib	CDK7	5100.0	68.0	9.999999999999999e-06
Sorafenib	AXL	4500.0	7.8	9.999999999999999e-06
R406	VGFR1	16.0	0.1	1e-06
R406	BLK	25.0	0.1	1e-06
NVP-TAE684	SRMS	160.0	0.0	1e-06
NVP-TAE684	FAK2	1.1	0.0	1e-06
Sorafenib	ABL1(Y253F)-phosphorylated	660.0	22.0	9.999999999999999e-06
R406	BRAF(V600E)	380.0	24.0	1e-06
GSK461364	RSK3(Kin.Dom.1-N-terminal)	1200.0	4.0	9.999999999999999e-06
Sorafenib	MKNK2	130.0	0.1	9.999999999999999e-06
NVP-TAE684	FLT3(K663Q)	8.2	0.3	1e-06
Neratinib	AXL	190.0	5.4	9.999999999999999e-06
Sorafenib	FGFR3(G697C)	5900.0	39.0	9.999999999999999e-06
R406	MAP4K2	670.0	28.0	1e-06
MLN8054	EPHA3	2100.0	15.0	9.999999999999999e-06
Sorafenib	ABL1(H396P)-phosphorylated	2400.0	35.0	9.999999999999999e-06
R406	CLK4	360.0	1.9	1e-06
PLX-4720	MP2K1	550.0	0.8	9.999999999999999e-06
NVP-TAE684	NUAK1	13.0	0.8	1e-06
Pictilisib	PIK3CA(E545K)	1.2	0.0	1.0000000000000002e-06
BI-2536	PLK3	4.0	0.0	9.999999999999999e-06
R406	MARK3	1900.0	7.2	1e-06
Barasertib	MLTK	1700.0	63.0	9.999999999999999e-06
Pictilisib	DYRK1B	3800.0	99.0	1.0000000000000002e-06
NVP-TAE684	CAMK1G	3000.0	31.0	1e-06
R406	LOK	70.0	0.4	1e-06
MLN8054	EGFR(L747-S752del,P753S)	6400.0	28.0	9.999999999999999e-06
Crizotinib	RIPK2	900.0	11.0	9.999999999999999e-06
NVP-TAE684	FYN	1400.0	5.6	1e-06
Lapatinib	EGFR(T790M)	860.0	18.0	9.999999999999999e-06
Neratinib	YSK1	12.0	13.0	9.999999999999999e-06
NVP-TAE684	MAP3K3	320.0	2.8	1e-06
R406	MP2K6	480.0	6.1	1e-06
Crizotinib	YES	770.0	17.0	9.999999999999999e-06
NVP-TAE684	CAMK1D	230.0	0.1	1e-06
R406	PLK4	4.2	1.5	1e-06
Barasertib	BTK	1200.0	7.2	9.999999999999999e-06
R406	RET	4.1	0.0	1e-06
NVP-TAE684	MYO3A	67.0	0.3	1e-06
GSK461364	KPCD3	1900.0	12.0	9.999999999999999e-06
Neratinib	PAK6	7500.0	74.0	9.999999999999999e-06
PLX-4720	SLK	5100.0	15.0	9.999999999999999e-06
MLN8054	CLK2	3200.0	7.4	9.999999999999999e-06
Sorafenib	ABL1-nonphosphorylated	130.0	0.2	9.999999999999999e-06
R406	BIKE	1900.0	1.8	1e-06
PLX-4720	NEK11	190.0	2.0	9.999999999999999e-06
R406	TSSK1	1000.0	3.0	1e-06
Neratinib	MET	4000.0	84.0	9.999999999999999e-06
Pictilisib	PIK3CD	5.0	0.0	1.0000000000000002e-06
Barasertib	ABL1(Q252H)-phosphorylated	6800.0	32.0	9.999999999999999e-06
Crizotinib	FAK2	190.0	1.1	9.999999999999999e-06
Sorafenib	TIE2	2100.0	15.0	9.999999999999999e-06
NVP-TAE684	TAOK1	25.0	0.1	1e-06
BI-2536	NEK7	6100.0	100.0	9.999999999999999e-06
NVP-TAE684	SRPK3	2900.0	1.7	1e-06
MLN8054	DAPK2	9100.0	41.0	9.999999999999999e-06
Crizotinib	TAOK1	1200.0	1.2	9.999999999999999e-06
Sorafenib	TNNI3K	280.0	19.0	9.999999999999999e-06
R406	FLT4	9.1	0.0	1e-06
PLX-4720	PTK6	48.0	0.5	9.999999999999999e-06
Neratinib	RSK1(Kin.Dom.1-N-terminal)	7400.0	57.0	9.999999999999999e-06
NVP-TAE684	SYK	1300.0	3.4	1e-06
Pictilisib	CLK2	600.0	55.0	1.0000000000000002e-06
Neratinib	MAST1	5500.0	100.0	9.999999999999999e-06
R406	ULK3	7.1	0.0	1e-06
NVP-TAE684	EGFR(L747-T751del,Sins)	79.0	0.6	1e-06
NVP-TAE684	MLK1	410.0	0.4	1e-06
BI-2536	CSNK1E	380.0	100.0	9.999999999999999e-06
Crizotinib	CASK	140.0	0.5	9.999999999999999e-06
Crizotinib	ULK2	1600.0	4.7	9.999999999999999e-06
NVP-TAE684	PAK1	650.0	4.8	1e-06
Sorafenib	EPHB6	240.0	3.0	9.999999999999999e-06
Pictilisib	CSNK1E	1200.0	75.0	1.0000000000000002e-06
Barasertib	ABL1(T315I)-phosphorylated	4800.0	31.0	9.999999999999999e-06
Neratinib	CSF1R	670.0	68.0	9.999999999999999e-06
Neratinib	MELK	1600.0	55.0	9.999999999999999e-06
NVP-TAE684	TNK2	2.0	0.0	1e-06
Crizotinib	TYRO3	800.0	4.6	9.999999999999999e-06
GSK461364	FLT3(R834Q)	4800.0	20.0	9.999999999999999e-06
NVP-TAE684	NEK9	800.0	3.3	1e-06
BI-2536	CSNK1D	1500.0	100.0	9.999999999999999e-06
MLN8054	RSK1(Kin.Dom.1-N-terminal)	4800.0	19.0	9.999999999999999e-06
R406	RIPK2	970.0	7.8	1e-06
Canertinib	AURKB	4200.0	100.0	1e-06
Neratinib	MP2K2	26.0	0.5	9.999999999999999e-06
Sorafenib	FLT3(ITD)	79.0	2.8	9.999999999999999e-06
NVP-TAE684	KPCD1	80.0	1.0	1e-06
GSK461364	FLT3(N841I)	690.0	1.2	9.999999999999999e-06
BMS345541	MYLK4	700.0	8.8	9.999999999999999e-06
Crizotinib	FLT3	850.0	7.8	9.999999999999999e-06
MLN8054	EPHA6	580.0	14.0	9.999999999999999e-06
Pictilisib	STK16	1100.0	81.0	1.0000000000000002e-06
Pictilisib	CDK16	1100.0	100.0	1.0000000000000002e-06
BI-2536	ERK5	3200.0	19.0	9.999999999999999e-06
Neratinib	MINK	29.0	6.8	9.999999999999999e-06
Barasertib	EGFR(L858R)	980.0	16.0	9.999999999999999e-06
Barasertib	MP2K5	2.8	0.4	9.999999999999999e-06
Pictilisib	HIPK1	1100.0	79.0	1.0000000000000002e-06
GSK461364	KPCI	5800.0	28.0	9.999999999999999e-06
Barasertib	KIT(L576P)	34.0	0.0	9.999999999999999e-06
NVP-TAE684	PRKX	5800.0	28.0	1e-06
PLX-4720	LYN	1100.0	24.0	9.999999999999999e-06
Canertinib	EPHA3	2100.0	100.0	1e-06
Barasertib	TTK	8500.0	49.0	9.999999999999999e-06
Barasertib	CHK2	1400.0	100.0	9.999999999999999e-06
PLX-4720	PGFRA	190.0	0.2	9.999999999999999e-06
GSK461364	PLK1	0.1	0.1	9.999999999999999e-06
NVP-TAE684	TNNI3K	2000.0	15.0	1e-06
Lapatinib	EGFR(G719S)	2.1	0.0	9.999999999999999e-06
Canertinib	BLK	45.0	10.0	1e-06
Sorafenib	FGFR1	2800.0	5.2	9.999999999999999e-06
Sorafenib	KIT(D816V)	310.0	3.6	9.999999999999999e-06
NVP-TAE684	EGFR(S752-I759del)	400.0	1.4	1e-06
Canertinib	DMPK	7000.0	100.0	1e-06
Canertinib	EGFR(L747-T751del,Sins)	0.26	0.0	1e-06
Crizotinib	AAK1	2300.0	21.0	9.999999999999999e-06
PLX-4720	ABL1(H396P)-nonphosphorylated	510.0	1.4	9.999999999999999e-06
Sorafenib	TAOK1	3100.0	23.0	9.999999999999999e-06
R406	EGFR	300.0	2.4	1e-06
Barasertib	MP2K2	4200.0	21.0	9.999999999999999e-06
R406	MARK2	280.0	5.5	1e-06
Barasertib	AXL	390.0	1.4	9.999999999999999e-06
PLX-4720	SRC	4700.0	9.2	9.999999999999999e-06
BMS345541	HIPK4	8100.0	41.0	9.999999999999999e-06
Neratinib	INSRR	4600.0	94.0	9.999999999999999e-06
R406	RIOK2	3400.0	16.0	1e-06
NVP-TAE684	MAP4K2	190.0	9.4	1e-06
R406	TXK	140.0	2.4	1e-06
MLN8054	SIK1	1700.0	5.7	9.999999999999999e-06
NVP-TAE684	TXK	480.0	6.9	1e-06
Barasertib	HIPK3	2500.0	29.0	9.999999999999999e-06
NVP-TAE684	GCN2(Kin.Dom.2,S808G)	1100.0	4.5	1e-06
Neratinib	KC1G2	6600.0	84.0	9.999999999999999e-06
Crizotinib	RIOK3	4000.0	3.4	9.999999999999999e-06
Canertinib	FLT3(N841I)	2400.0	100.0	1e-06
Barasertib	ERBB4	470.0	4.0	9.999999999999999e-06
NVP-TAE684	CDK2	5200.0	24.0	1e-06
Neratinib	CSNK1E	290.0	26.0	9.999999999999999e-06
MLN8054	ABL1-nonphosphorylated	1100.0	2.8	9.999999999999999e-06
Neratinib	HCK	490.0	35.0	9.999999999999999e-06
R406	AXL	82.0	0.4	1e-06
R406	CSNK2A2	14.0	1.9	1e-06
Sorafenib	ABL1(H396P)-nonphosphorylated	520.0	1.1	9.999999999999999e-06
Crizotinib	MET(Y1235D)	1.5	1.7	9.999999999999999e-06
BI-2536	LOK	4900.0	100.0	9.999999999999999e-06
Neratinib	NUAK1	1500.0	61.0	9.999999999999999e-06
NVP-TAE684	DDR1	140.0	0.1	1e-06
Barasertib	PLK4	4700.0	9.6	9.999999999999999e-06
R406	TESK1	360.0	19.0	1e-06
Canertinib	ERK3	1700.0	100.0	1e-06
NVP-TAE684	BMPR2	3900.0	100.0	1e-06
R406	CAMK1G	460.0	19.0	1e-06
R406	CAMK1D	200.0	2.2	1e-06
NVP-TAE684	TGFBR1	190.0	0.2	1e-06
Sorafenib	CDK11	250.0	1.4	9.999999999999999e-06
Sorafenib	TRKC	600.0	0.7	9.999999999999999e-06
Canertinib	CSK	6100.0	100.0	1e-06
Canertinib	SIK2	4900.0	100.0	1e-06
R406	FGFR3(G697C)	67.0	0.6	1e-06
NVP-TAE684	MAP3K4	2000.0	13.0	1e-06
NVP-TAE684	MET	170.0	0.0	1e-06
NVP-TAE684	PLK1	20.0	0.1	1e-06
Sorafenib	EPHB2	1900.0	17.0	9.999999999999999e-06
BI-2536	EGFR(G719S)	1300.0	29.0	9.999999999999999e-06
Lapatinib	EGFR	2.4	0.0	9.999999999999999e-06
Neratinib	TIE1	390.0	24.0	9.999999999999999e-06
NVP-TAE684	PAK6	3500.0	13.0	1e-06
Sorafenib	STK33	2400.0	33.0	9.999999999999999e-06
GSK461364	RIOK3	2300.0	6.6	9.999999999999999e-06
R406	MUSK	100.0	0.2	1e-06
Sorafenib	CDKL2	130.0	0.3	9.999999999999999e-06
NVP-TAE684	MP2K3	170.0	0.8	1e-06
Neratinib	FER	510.0	37.0	9.999999999999999e-06
Crizotinib	FYN	1300.0	10.0	9.999999999999999e-06
Canertinib	TYRO3	1000.0	100.0	1e-06
R406	AURKB	110.0	0.5	1e-06
R406	PCTK2	330.0	12.0	1e-06
Neratinib	JAK3(JH1domain-catalytic)	2000.0	100.0	9.999999999999999e-06
MLN8054	FER	4400.0	22.0	9.999999999999999e-06
BI-2536	PRKR	460.0	100.0	9.999999999999999e-06
Canertinib	EPHA6	270.0	100.0	1e-06
Pictilisib	CLK1	1100.0	59.0	1.0000000000000002e-06
PLX-4720	FGFR1	5300.0	34.0	9.999999999999999e-06
Neratinib	PAK1	210.0	16.0	9.999999999999999e-06
NVP-TAE684	EPHB2	1500.0	33.0	1e-06
NVP-TAE684	FLT3(D835Y)	2.0	0.1	1e-06
PLX-4720	RIPK2	430.0	8.3	9.999999999999999e-06
PLX-4720	TGFBR2	890.0	6.6	9.999999999999999e-06
Lapatinib	MP2K5	1100.0	12.0	9.999999999999999e-06
NVP-TAE684	EPHB4	750.0	17.0	1e-06
Canertinib	EGFR(G719S)	0.19	0.0	1e-06
NVP-TAE684	RIPK2	9600.0	100.0	1e-06
Crizotinib	LTK	12.0	0.3	9.999999999999999e-06
R406	PAK2	340.0	26.0	1e-06
Neratinib	MLK1	5400.0	84.0	9.999999999999999e-06
Sorafenib	EPHA2	2000.0	18.0	9.999999999999999e-06
Crizotinib	GRK4	4200.0	14.0	9.999999999999999e-06
Barasertib	ABL1(H396P)-nonphosphorylated	1200.0	1.2	9.999999999999999e-06
NVP-TAE684	VGFR2	940.0	2.2	1e-06
R406	NEK7	11.0	0.8	1e-06
Crizotinib	MINK	4400.0	18.0	9.999999999999999e-06
Barasertib	CDC2L2	1000.0	5.0	9.999999999999999e-06
PLX-4720	MLTK	41.0	6.0	9.999999999999999e-06
NVP-TAE684	CSK	1800.0	2.0	1e-06
Crizotinib	IRAK1	49.0	0.0	9.999999999999999e-06
PLX-4720	FRK	1900.0	19.0	9.999999999999999e-06
R406	GAK	250.0	5.9	1e-06
Barasertib	RET(V804M)	240.0	5.5	9.999999999999999e-06
NVP-TAE684	LATS1	1600.0	32.0	1e-06
NVP-TAE684	ERBB4	280.0	1.2	1e-06
PLX-4720	FYN	2300.0	11.0	9.999999999999999e-06
NVP-TAE684	SgK110	54.0	0.0	1e-06
Canertinib	TGFBR2	800.0	100.0	1e-06
R406	IKKB	71.0	2.0	1e-06
R406	KIT(V559D)	5.7	0.0	1e-06
NVP-TAE684	ULK2	1.8	1.1	1e-06
PLX-4720	YES	1800.0	18.0	9.999999999999999e-06
Crizotinib	ABL1(T315I)-phosphorylated	10.0	0.6	9.999999999999999e-06
NVP-TAE684	MST2	310.0	0.3	1e-06
BMS345541	ERN1	1000.0	88.0	9.999999999999999e-06
GSK461364	ROCK1	4900.0	7.9	9.999999999999999e-06
NVP-TAE684	ALK	1.1	0.3	1e-06
GSK461364	KIT(D816V)	1600.0	16.0	9.999999999999999e-06
Neratinib	EGFR(L858R)	0.7	0.0	9.999999999999999e-06
R406	IKKE	13.0	2.7	1e-06
Sorafenib	RET(V804M)	22.0	0.0	9.999999999999999e-06
Crizotinib	FLT3(ITD)	730.0	31.0	9.999999999999999e-06
Barasertib	KIT	17.0	0.0	9.999999999999999e-06
NVP-TAE684	PKN2	680.0	3.2	1e-06
NVP-TAE684	CAMK2G	780.0	2.0	1e-06
Canertinib	AURKC	2800.0	100.0	1e-06
MLN8054	ABL1(Y253F)-phosphorylated	1000.0	8.2	9.999999999999999e-06
Pictilisib	YSK4	4000.0	95.0	1.0000000000000002e-06
R406	IRAK3	11.0	0.4	1e-06
MLN8054	ROS1	3100.0	23.0	9.999999999999999e-06
R406	LKB1	3400.0	100.0	1e-06
PLX-4720	RIPK1	5100.0	53.0	9.999999999999999e-06
NVP-TAE684	SRC	280.0	0.2	1e-06
Crizotinib	BLK	110.0	1.2	9.999999999999999e-06
Crizotinib	MAP4K2	80.0	0.0	9.999999999999999e-06
NVP-TAE684	TSSK1	25.0	0.0	1e-06
BI-2536	EGFR(L747-T751del,Sins)	4800.0	19.0	9.999999999999999e-06
Lapatinib	ERBB4	54.0	0.2	9.999999999999999e-06
MLN8054	FYN	1300.0	17.0	9.999999999999999e-06
Neratinib	FYN	6400.0	84.0	9.999999999999999e-06
Barasertib	HIPK4	97.0	4.5	9.999999999999999e-06
MLN8054	AURKA	6.5	0.5	9.999999999999999e-06
Crizotinib	JAK2(JH1domain-catalytic)	290.0	1.4	9.999999999999999e-06
Crizotinib	IKKB	5500.0	14.0	9.999999999999999e-06
Sorafenib	MK13	6600.0	7.6	9.999999999999999e-06
Sorafenib	KIT(V559D,V654A)	240.0	1.1	9.999999999999999e-06
Crizotinib	AURKA	260.0	3.2	9.999999999999999e-06
NVP-TAE684	FES	4.8	0.3	1e-06
Barasertib	CSF1R	1400.0	5.0	9.999999999999999e-06
BI-2536	GAK	180.0	1.6	9.999999999999999e-06
Crizotinib	EPHA8	280.0	0.2	9.999999999999999e-06
Canertinib	GAK	100.0	5.4	1e-06
NVP-TAE684	EGFR(L747-S752del,P753S)	110.0	1.0	1e-06
NVP-TAE684	RET(V804L)	120.0	0.3	1e-06
Pictilisib	FLT3(N841I)	3900.0	100.0	1.0000000000000002e-06
PLX-4720	PFCDPK1(P.falciparum)	1.7	0.0	9.999999999999999e-06
Pictilisib	CSNK1D	1200.0	66.0	1.0000000000000002e-06
Barasertib	ABL1(F317L)-nonphosphorylated	1400.0	5.4	9.999999999999999e-06
Crizotinib	EPHB6	6.0	0.2	9.999999999999999e-06
Pictilisib	DYRK2	7600.0	100.0	1.0000000000000002e-06
Pictilisib	CLK4	1500.0	56.0	1.0000000000000002e-06
BMS345541	CDC2L5	800.0	4.7	9.999999999999999e-06
PLX-4720	FGFR2	3100.0	59.0	9.999999999999999e-06
NVP-TAE684	ROS1	0.5	0.5	1e-06
R406	DAPK3	13.0	1.2	1e-06
BI-2536	RIOK3	4400.0	100.0	9.999999999999999e-06
BI-2536	MET	2400.0	34.0	9.999999999999999e-06
BMS345541	PKNB(M.tuberculosis)	2400.0	0.0	9.999999999999999e-06
R406	EPHA1	67.0	1.9	1e-06
R406	EGFR(L747-E749del,A750P)	260.0	0.8	1e-06
Sorafenib	KIT(V559D)	16.0	0.1	9.999999999999999e-06
NVP-TAE684	MLK3	420.0	20.0	1e-06
BI-2536	CHK2	7700.0	100.0	9.999999999999999e-06
NVP-TAE684	TYRO3	7200.0	24.0	1e-06
Canertinib	FGR	2800.0	100.0	1e-06
Sorafenib	ABL1(F317I)-nonphosphorylated	1700.0	5.6	9.999999999999999e-06
R406	HCK	150.0	0.5	1e-06
R406	TAK1	49.0	0.2	1e-06
R406	MKNK2	130.0	0.0	1e-06
Crizotinib	MAP3K1	1100.0	4.4	9.999999999999999e-06
NVP-TAE684	FRK	27.0	0.2	1e-06
GSK461364	SLK	1100.0	0.3	9.999999999999999e-06
Neratinib	FLT3(K663Q)	4900.0	77.0	9.999999999999999e-06
Canertinib	TNNI3K	5600.0	100.0	1e-06
R406	MLK2	3.8	0.0	1e-06
NVP-TAE684	IKKE	1100.0	25.0	1e-06
Crizotinib	JAK3(JH1domain-catalytic)	200.0	0.7	9.999999999999999e-06
Crizotinib	EPHA4	360.0	6.0	9.999999999999999e-06
Crizotinib	ULK1	1000.0	1.0	9.999999999999999e-06
PLX-4720	DCLK1	8100.0	52.0	9.999999999999999e-06
BI-2536	EGFR(L861Q)	2700.0	100.0	9.999999999999999e-06
R406	PIK3CD	4200.0	29.0	1e-06
Neratinib	MST2	58.0	1.4	9.999999999999999e-06
NVP-TAE684	KPCT	1500.0	13.0	1e-06
NVP-TAE684	STK33	3.2	0.1	1e-06
NVP-TAE684	FAK1	1.1	0.0	1e-06
Canertinib	ITK	5600.0	100.0	1e-06
Crizotinib	BMPR1B	230.0	0.2	9.999999999999999e-06
Crizotinib	SYK	2500.0	10.0	9.999999999999999e-06
BMS345541	STK36	6500.0	28.0	9.999999999999999e-06
NVP-TAE684	MERTK	19.0	0.0	1e-06
R406	DDR1	9.3	0.0	1e-06
NVP-TAE684	JNK1	160.0	5.2	1e-06
NVP-TAE684	LOK	82.0	0.0	1e-06
Crizotinib	TRKB	37.0	0.2	9.999999999999999e-06
Sorafenib	EPHB4	1800.0	21.0	9.999999999999999e-06
R406	CLK1	1200.0	1.4	1e-06
Crizotinib	PRKR	1100.0	43.0	9.999999999999999e-06
Neratinib	FES	590.0	37.0	9.999999999999999e-06
Neratinib	MLK2	4600.0	88.0	9.999999999999999e-06
NVP-TAE684	FLT3(N841I)	11.0	0.5	1e-06
NVP-TAE684	FLT3	15.0	0.1	1e-06
Neratinib	CHK2	850.0	79.0	9.999999999999999e-06
Crizotinib	AURKC	4300.0	3.4	9.999999999999999e-06
